register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 ⌀ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 ⌀ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT00889460 | [
{
"id_field": "org_study_id",
"id_value": [
"VO58.07 DK"
]
}
] | https://clinicaltrials.gov/study/NCT00889460 | Safety and Tolerability Study of rBet v1 SLIT Tablets | The purpose of this study is to determine the safety and tolerability of several doses of r Bet v1 administered as sub-lingual tablets in subjects sensitised to birch pollen. | Phase I Study to re-Investigate the Safety, Tolerability and Pharmacodynamic Effects of SLIT(Tablets) With Recombinant Bet v1 Given in Single Rising Doses and in Multi Dose Regimens to Subjects Sensitised to Birch Pollen | [
{
"description": "Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.",
"name": "rBet v 1",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
... | [
{
"design_group_description": "Placebo group",
"design_group_title": "1",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_description": "Two matching placebo tablets were administere... | [
"Birch Pollen-Related Rhinoconjunctivitis",
"Rhinitis, Allergic, Seasonal"
] | [
"Stallergenes Greer Ltd."
] | [
"Quintiles, Inc. (California)"
] | [
[
{
"name": "Birch pollen allergen product(Stallergenes GmbH)",
"lang": "EN"
}
]
] | null |
NCT03881488 | [
{
"id_field": "org_study_id",
"id_value": [
"CTX-471-001"
]
},
{
"id_domain": "Merck, Sharp & Dohme, LLC, Rahway, NJ USA",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"KEYNOTE-E65"
]
},
{
"id_domain": "Merck, Sharp & Dohme, LLC, Ra... | https://clinicaltrials.gov/study/NCT03881488 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving an approved PD-1 or PD-L1 inhibitor. The study will be conducted in 2 treatment arms (Monoth... | A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies | [
{
"description": "IV infusion every 2 weeks",
"name": "CTX-471",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "IV infusion every 6 weeks",
"name": "Pembrolizumab (KEYTRUDA®)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"oth... | [
{
"design_group_description": "Escalating doses of CTX-471 depending on cohort at enrollment",
"design_group_title": "Arm 1 Part 1 Dose Escalation",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"inte... | [
"Locally Advanced Solid Tumor",
"Metastatic Cancer",
"Non-small Cell Lung Cancer",
"Small Cell Lung Cancer",
"Mesothelioma",
"Melanoma",
"Head and Neck Cancer"
] | [
"Compass Therapeutics, Inc."
] | [
"IQVIA Holdings, Inc."
] | [
[
{
"name": "CTX-471",
"lang": "EN"
}
],
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name": "ペムブロリズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "e834a2a388eded8d9eda58e450d8e5aa",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "CTX-471-001"
}
] |
NCT00058578 | [
{
"id_field": "org_study_id",
"id_value": [
"H7157"
]
},
{
"id_field": "secondary_id",
"id_value": [
"Systemic Sclerosis"
]
}
] | https://clinicaltrials.gov/study/NCT00058578 | Stem Cell Transplant to Treat Patients With Systemic Sclerosis | Systemic Sclerosis is a disease that may be caused by the immune system reacting against skin and certain organs. It is possible, that by changing the immune system we can modify the progression of this disease.<br/>Stem cells are created in the bone marrow. They mature into different types of blood cells that are need... | Autologous T-Cell Depleted Peripheral Blood Stem Cell Transplantation for the Treatment of Selected Patients With Systemic Sclerosis | [
{
"name": "Cyclophosphamide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "Mesna",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name":... | null | [
"Systemic Sclerosis"
] | [
"Baylor College of Medicine"
] | [
"Center For Cell & Gene Therapy",
"The Methodist Hospital Research Institute"
] | [
[
{
"name": "美司钠",
"lang": "CN"
},
{
"name": "Mesna",
"lang": "EN"
},
{
"name": "メスナ",
"lang": "JP"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
},
{
"name": "シクロホ... | null |
NCT05657184 | [
{
"id_field": "org_study_id",
"id_value": [
"XHYX-IND-IPF-P1"
]
}
] | https://clinicaltrials.gov/study/NCT05657184 | Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001 | Idiopathic pulmonary fibrosis (IPF) is a condition where the lungs are damaged and scarred with unknown reason, making breathing becomes increasingly difficult.. REGEND001, made from airway basal cells with ability to regenerate lung tissue, is promising to IPF treatment. In this study, a single-armed clinical trial is... | An Open-label Clinical Study to Explore the Safety, Tolerability and Preliminary Efficacy of REGEND001 for Treatment of Idiopathic Pulmonary Fibrosis (IPF). | [
{
"description": "Transplantation of REGEND001 for dose escalation.",
"name": "REGEND001",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Transplantation of autologous airway basal cells",
"design_group_title": "REGEND001",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Transpla... | [
"Idiopathic Pulmonary Fibrosis"
] | [
"Regend Therapeutics Co. Ltd."
] | [
"Ruijin Hospital",
"Peking Union Medical College Hospital",
"The First Affiliated Hospital of Guangzhou Medical University"
] | [
[
{
"name": "REGEND001细胞自体回输制剂",
"lang": "CN"
},
{
"name": "Pulmovinci",
"lang": "EN"
}
]
] | null |
NCT04782076 | [
{
"id_field": "org_study_id",
"id_value": [
"17972"
]
},
{
"id_domain": "Eli Lilly and Company",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"J2G-MC-JZJV"
]
}
] | https://clinicaltrials.gov/study/NCT04782076 | A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants | The main purpose of this study is to determine the effect of selpercatinib on the levels of dabigatran in the blood stream and how long it takes the body to remove dabigatran. This study will also look at how safe and well-tolerated of dabigatran when administered in combination with selpercatinib in healthy participan... | An Open-Label Study to Investigate the Effect of Selpercatinib on the Pharmacokinetics of Dabigatran in Healthy Volunteers | [
{
"description": "Administered orally.",
"name": "Dabigatran",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Administered orally.",
"name": "Selpercatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"... | [
{
"design_group_description": "Participants received a single oral dose of 150 milligrams (mg) dabigatran on Day 1 and a single oral dose of 150 mg dabigatran coadministered with a single oral dose of 2 x 80 mg (160 mg) selpercatinib on Day 8.<br/>There was a washout period of 7 days between dosing on Days 1 an... | [
"Healthy"
] | [
"Loxo Oncology, Inc."
] | [
"Eli Lilly & Co."
] | [
[
{
"name": "塞普替尼",
"lang": "CN"
},
{
"name": "Selpercatinib",
"lang": "EN"
},
{
"name": "セルペルカチニブ",
"lang": "JP"
}
],
[
{
"name": "甲磺酸达比加群酯",
"lang": "CN"
},
{
"name": "Dabigatran Etexilate Mesylate",
"lang": "EN"
... | null |
NCT00648128 | [
{
"id_field": "org_study_id",
"id_value": [
"CAI-P2-316"
]
}
] | https://clinicaltrials.gov/study/NCT00648128 | Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Fed State | The objective of this study was to investigate the bioequivalence of Genpharm's clarithromycin tablets following a single, oral 500 mg (1 x 500 mg) dose compared to the Biaxin® filmtab® (Abbott Laboratories USA) administered under fed conditions. Forty-four (44) healthy, light-, non- or ex-smoking subjects of at least ... | Single Dose Crossover Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Healthy Male and Female Volunteers / Fed State | [
{
"description": "Single-dose 500 mg immediate-release oral tablet",
"name": "Clarithromycin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "single-dose 500 mg immediate-release oral dose'",
"name": "Clarithromycin",
"normalized_type": "3d... | [
{
"design_group_title": "2",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "single-dose 500 mg immediate-release oral dose'",
"intervention_name": "Clarithromycin"... | [
"Healthy"
] | [
"Mylan Pharmaceuticals, Inc."
] | [
"Genpharm ULC"
] | [
[
{
"name": "克拉霉素",
"lang": "CN"
},
{
"name": "Clarithromycin",
"lang": "EN"
},
{
"name": "クラリスロマイシン",
"lang": "JP"
}
]
] | null |
NCT05963217 | [
{
"id_field": "org_study_id",
"id_value": [
"TBI-200101"
]
}
] | https://clinicaltrials.gov/study/NCT05963217 | Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL | This is a Phase 1/1b, open-label, dose-escalation study to evaluate the safety and the efficacy of anti-CD19 chimeric antigen receptor (CAR) (TBI-2001) for relapsed or refractory CD19+ B-cell lymphoma Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL). | Phase I/Ib Study of TBI-2001 for Patients With Relapsed or Refractory CD19+ B-cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | [
{
"description": "Phase-I portion:<br/>cohort 1: 3×10^5 cells/kg, cohort 2: 1×10^6 cells/kg, cohort 3: 3×10^6 cells/kg). Phase-Ib portion: The dose of Phase-Ib will be determined during the phase I portion.",
"name": "TBI-2001",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"single_or_multi... | [
{
"design_group_description": "0.3 to 3 x 10^6 autologous CD19-CAR-T cells/kg per patient will be administered intravenously after a conditioning chemotherapy with cyclophosphamide and fludarabine.",
"design_group_title": "Experimental: Dose Level 1 to 3",
"design_group_type": "Experimental",
"desig... | [
"Relapsed or Refractory CD19+ B-cell Lymphoma",
"Relapsed or Refractory Chronic Lymphocytic Leukemia",
"Relapsed or Refractory Small Lymphocytic Lymphoma"
] | [
"University Health Network"
] | [
"Takara Bio, Inc."
] | [
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang": "JP"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
... | null |
NCT01585181 | [
{
"id_field": "org_study_id",
"id_value": [
"PXVX-VC-0200-002"
]
}
] | https://clinicaltrials.gov/study/NCT01585181 | Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 | The purpose of this study is to compare the safety and immunogenicity of a single dose of the PXVX0200 live cholera vaccine versus placebo in volunteers (Vaccinees) and whether PXVX0200, which is a live attenuated bacteria, can be transmitted to other adults living in the same household. | A Phase 1 Randomized, Double-Blind Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the LIve Oral Cholera Vaccine Candidate PXVX0200 Vibrio Cholerae Serotype 01 Inaba CVD 103-HgR Vaccine Strain | [
{
"description": "Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension",
"name": "PXVX0200",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Approx 2 grams of lactose reconstituted in water... | [
{
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_description": "Approx 2 grams of lactose reconstituted in water",
"intervention_name": "Placebo... | [
"Cholera"
] | [
"Bavarian Nordic A/S"
] | [
"Emergent BioSolutions, Inc."
] | [
[
{
"name": "活霍乱疫苗",
"lang": "CN"
},
{
"name": "Cholera Vaccine Live Oral(Emergent Travel Health)",
"lang": "EN"
}
]
] | null |
NCT05414786 | [
{
"id_field": "org_study_id",
"id_value": [
"IAVI G003"
]
}
] | https://clinicaltrials.gov/study/NCT05414786 | A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) | A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) in HIV-1 Uninfected Adults in Good General Health. | A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) in HIV-1 Uninfected Adults in Good General Health | [
{
"description": "* 2 doses eOD-GT8 60mer mRNA Vaccine (100µg), 2 vaccinations, 8 weeks apart<br/>* No control group. There is no blinding and no randomization in this open label study",
"name": "eOD-GT8 60mer mRNA Vaccine (100µg)",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Bio... | [
{
"design_group_description": "* 2 doses eOD-GT8 60mer mRNA Vaccine (100µg), 2 vaccinations, 8 weeks apart<br/>* No control group. There is no blinding and no randomization in this open label study",
"design_group_title": "Experimental group",
"design_group_type": "Experimental",
"design_group_type_... | [
"HIV-1-infection"
] | [
"International AIDS Vaccine Initiative, Inc."
] | [
"The Aurum Institute",
"ModernaTX, Inc.",
"Center For Family Health"
] | [
[
{
"name": "mRNA-1644",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "e2a382d8e2e229d0255e092952424248",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "IAVI G003"
}
] |
NCT07232420 | [
{
"id_field": "org_study_id",
"id_value": [
"BL-M24D1-101"
]
}
] | https://clinicaltrials.gov/study/NCT07232420 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors | This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M24D1 in patients with locally advanced or metastatic non-small cell lung cancer and other solid tumors. | A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M24D1 for Injection in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors | [
{
"description": "Administration by intravenous infusion for a cycle of 2 weeks.",
"name": "BL-M24D1",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Participants receive BL-M24D1 as intravenous infusion for the first cycle (2 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or oth... | [
"Non Small Cell Lung Cancer",
"Solid Tumor"
] | [
"Sichuan Baili Pharmaceuticals Co.,Ltd"
] | [
"Baili Bio Chengdu Pharmaceutical Co. Ltd."
] | [
[
{
"name": "BL-M24D1",
"lang": "EN"
}
]
] | null |
NCT03498222 | [
{
"id_field": "org_study_id",
"id_value": [
"012375QM"
]
},
{
"id_field": "acronym",
"id_value": [
"iTRAP"
]
}
] | https://clinicaltrials.gov/study/NCT03498222 | Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin | iTRAP is an open-label, multi-centre, dose escalation study of ADI PEG20 in combination with atezolizumab, pemetrexed and carboplatin in patients with advanced non-squamous non-small cell lung carcinoma (NSCLC) - stage IIIB/IV. | Phase I Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin (ADIAtezoPemCarbo) (iTRAP Study) | [
{
"description": "Administered at a fixed dose of 1200 mg (equivalent to an average body weight-based dose of 15mg/kg) by intravenous (IV) infusion every 3 weeks (21 days).",
"name": "Atezolizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Tecentriq"
],
"... | [
{
"design_group_description": "Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 9mg/m2",
"design_group_title": "Dose Level -1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interve... | [
"Carcinoma, Non-Small-Cell Lung"
] | [
"Queen Mary University of London"
] | [
"Polaris Group",
"Hoffmann-La Roche, Inc."
] | [
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
"name": "カルボプラチン",
"lang": "JP"
}
],
[
{
"name": "培美曲塞二钾",
"lang": "CN"
},
{
"name": "Pemetrexed Dipotassium",
"lang": "EN"
}
],
[
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "iTRAP"
}
] |
NCT00871533 | [
{
"id_field": "org_study_id",
"id_value": [
"08-067"
]
}
] | https://clinicaltrials.gov/study/NCT00871533 | Pilot Study of IFN α2b for Melanoma Patients | The presence of malignant cells in lymph nodes is a critical parameter in the staging of melanoma cancer patients. Assessment of lymph nodes is currently done by histopathology alone. The long-term survival of melanoma cancer patients who have Stage IB disease (no known lymph node involvement with a tumor greater than ... | Pilot Analysis of the Effects of IFN α2b Upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients With and Without Tumor-Involved Sentinel Lymph Nodes | [
{
"description": "IV injection at 20 million IU/m2. IFNα2b IV injection will be performed every day between day -14 and day -9 (5 infusions) and also every day between day -7 and day -2 (5 infusions) for a total of 10 infusions.",
"name": "IFNα2b",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "REGIONAL PEG IFN MAINTENANCE: Regional PEG IFN-a2b given subcutaneously at \"MAINTENANCE\" dose level. (This arm has completed enrollment; non-evaluable subjects as defined in section 9.5 may be replaced at any point during study.",
"design_group_title": "1",
"design_group... | [
"Melanoma"
] | [
"University of Pittsburgh"
] | [
"Schering-Plough Corp."
] | [
[
{
"name": "重组人干扰素α-2b(Merck Sharp & Dohme )",
"lang": "CN"
},
{
"name": "INTERFERON ALFA-2B(Merck Sharp & Dohme )",
"lang": "EN"
}
],
[
{
"name": "聚乙二醇干扰素α-2b注射(Merck & Co)",
"lang": "CN"
},
{
"name": "Peginterferon alfa-2b(Merck & Co)",
... | null |
NCT03661125 | [
{
"id_field": "org_study_id",
"id_value": [
"247303"
]
},
{
"id_field": "acronym",
"id_value": [
"SCRIPT"
]
}
] | https://clinicaltrials.gov/study/NCT03661125 | SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis | Parkinson's disease is often characterised by movement symptoms such as rigidity and bradykinesia, however, there are a number of non-motor symptoms that can have a significant impact on quality of life. One of the most common non-motor symptoms of Parkinson's disease is visual hallucinations (where someone sees things... | A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis. | [
{
"description": "AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49. Two tablets to be taken every morning for 14 days.",
"name": "Saracatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo AZD0530 (Saracatinib) 50 mg Tab... | [
{
"design_group_description": "In the first arm of the study, participants will be randomised into either the group that receives Saracatinib (study drug) or the Placebo.",
"design_group_title": "Saracatinib or placebo",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b55... | [
"Parkinson Disease Psychosis"
] | [
"King's College London"
] | [
"King's College Hospital NHS Foundation Trust",
"AstraZeneca PLC"
] | [
[
{
"name": "塞卡替尼",
"lang": "CN"
},
{
"name": "Saracatinib",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SCRIPT"
}
] |
NCT07421102 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro00146867"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"K12DA031794"
]
}
] | https://clinicaltrials.gov/study/NCT07421102 | Pilot of Mailing Buprenorphine | This pilot study evaluates the feasibility, acceptability, and preliminary effectiveness of mailing buprenorphine to individuals with opioid use disorder (OUD) following medical hospitalization. The intervention aims to improve retention in treatment by overcoming barriers such as transportation and pharmacy access. | A Pragmatic Remote Approach to Improve Transitions of Care and Retention in Opioid Use Disorder Treatment | [
{
"description": "This study examines the feasibility and preliminary effectiveness of mailing buprenorphine to overcome barriers such as transportation to obtaining buprenorphine from a pharmacy.",
"name": "strategy of mailing buprenorphine",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"... | [
{
"design_group_description": "There is no comparison arm. This pilot study evaluates the feasibility of mailing medications to patients.",
"design_group_title": "Mailed Medications",
"design_group_type": "Other",
"intervention": [
{
"intervention_description": "This study examines the... | [
"Opioid Use Disorder"
] | [
"The Medical University of South Carolina"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "盐酸丁丙诺啡",
"lang": "CN"
},
{
"name": "Buprenorphine Hydrochloride",
"lang": "EN"
},
{
"name": "ブプレノルフィン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT03131934 | [
{
"id_field": "org_study_id",
"id_value": [
"UCL/16/0529"
]
},
{
"id_field": "acronym",
"id_value": [
"ITREC"
]
}
] | https://clinicaltrials.gov/study/NCT03131934 | Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant | This is an open label, non-randomised, multicentre Phase I to determine the safety of tacrolimus-resistant autologous EBV-specific cytotoxic T-cells (EBV CTL) and compare their expansion/persistence with control EBV CTL in solid organ transplant patients with post-transplant lymphoproliferative disease (PTLD). Each pat... | Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant | [
{
"description": "Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12 conferring resistance to tacrolimus",
"name": "Autologous EBV-CTL transduced with vector SFG-CNA12",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
... | [
{
"design_group_description": "All patients will receive the autologous EBV CTL retrovirally transduced with with (a) a calcineurin mutant (CNA12) that confers resistance to tacrolimus and (b) a control calcineurin mutant (CNA8). For each patient two ATIMPs will be generated:<br/>* Autologous EBV-specific cytot... | [
"Post-transplant Lymphoproliferative Disease",
"Transplant-Related Hematologic Malignancy"
] | [
"University College London"
] | [
"Genetix Biotherapeutics, Inc."
] | [
[
{
"name": "Autologous EBV-specific cytotoxic T-cells(bluebird)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ITREC"
}
] |
NCT01308242 | [
{
"id_field": "org_study_id",
"id_value": [
"33139CS"
]
}
] | https://clinicaltrials.gov/study/NCT01308242 | Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease | Fibroblast Growth Factor 23 (FGF23) is a molecule that has been implicated in the homeostasis of phosphorus. Elevated FGF23 levels are well-documented in patients with Chronic Kidney Disease (CKD) and are inversely correlated with Glomerular Filtration Rate (GFR). FGF23 levels are also predictive of progression of CKD ... | Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease | [
{
"description": "Sevelamer 800 mg by mouth three times daily with meals for 3 months",
"name": "Sevelamer Carbonate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Renvela"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Patients enrolled will receive Renvela for a 3 month time frame.",
"design_group_title": "Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descrip... | [
"Chronic Kidney Disease"
] | [
"Hershey Medical Center"
] | [
"Genzyme Corp."
] | [
[
{
"name": "碳酸司维拉姆",
"lang": "CN"
},
{
"name": "Sevelamer Carbonate",
"lang": "EN"
}
]
] | null |
NCT07052760 | [
{
"id_field": "org_study_id",
"id_value": [
"25926"
]
},
{
"id_domain": "NCI Clinical Trials Reporting Program (CTRP)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2025-04590"
]
}
] | https://clinicaltrials.gov/study/NCT07052760 | Imaging of Solid Tumors Using DLL3 SPECT | This is a single arm, pilot trial that evaluates the ability of a novel imaging agent (111In-ABD147) to detect metastatic cancer in participants with solid tumors. 111In-ABD147 is a high affinity Delta-like ligand 3 (DLL3) antigen binding domain fused to an engineered humanized Fc to create an antibody (VHH-Fc) that is... | Imaging of Solid Tumors Using DLL3 SPECT | [
{
"description": "Given intravenously (IV) prior to imaging",
"name": "111In-ABD147",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Radioimmunoconjugate"
],
"type": "Drug"
},
{
"description": "Undergo imaging",
"name": "Single-photon emission compu... | [
{
"design_group_description": "Participants will receive a single administration of 185 megabecquerels (MBq) (5 millicurie (mCi)) +/- 10% of 111In-ABD147 prior to SPECT/CT imaging 48 hours after injection. Repeat administration of 111In-ABD147 and SPECT/CT imaging may be performed. Participants will be followed... | [
"Solid Tumor Cancer",
"Castration Resistant Prostate Cancer",
"Castration Resistant Prostate Cancer (CRPC)",
"Neuroendocrine (NE) Tumors"
] | [
"The University of California, San Francisco"
] | [
"Abdera Therapeutics, Inc."
] | [
[
{
"name": "ABD-147",
"lang": "EN"
}
]
] | null |
NCT06639191 | [
{
"id_field": "org_study_id",
"id_value": [
"AKIR001"
]
},
{
"id_field": "secondary_id",
"id_type": "EU Trial (CTIS) Number",
"id_value": [
"2023-508126-95-00"
]
},
{
"id_field": "acronym",
"id_value": [
"AKIR001"
]
},
{
"id_field": "secondar... | https://clinicaltrials.gov/study/NCT06639191 | [177Lu]Lu-AKIR001 First-in-human Study | The goal of this clinical trial is to evaluate the safety and tolerability of increasing doses of [177Lu]Lu-AKIR001, both in relation to tolerable activity of lutetium-177 and the absorbed protein mass dose of AKIR-001 in patients with irresectable or metastatic CD44v6-expressing solid malignancies for whom no reasonab... | A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and Its Anti-tumour Effect in Adult Patients With CD44v6 Expressing Solid Tumours | [
{
"description": "Patient cohorts of a minimum of three and a maximum of 12 evaluable participants will be opened according to the decision tree defined in the protocol and will be consecutively completed. When one cohort has been completed and fully evaluated, the next cohort will be opened after all participa... | [
{
"design_group_description": "In the successive cohorts, increasing doses of radioactivity (177-Lu) and CD44v6-targeted antibody (AKIR001) are given. A new dose cohort is opened only when toxicity in the previous dose cohort has deemed acceptable by the trial steering committee and the independent Data Safety ... | [
"Thyroid Gland Anaplastic Carcinoma",
"Poorly Differentiated Thyroid Carcinoma",
"Cancer Head and Neck",
"Cervix Carcinoma",
"Vulvar Cancer, Stage IV",
"Non-small Cell Lung Cancer Stage IV"
] | [
"Karolinska University Hospital"
] | [
"Karolinska Institutet",
"University of Uppsala"
] | [
[
{
"name": "[177Lu]Lu-AKIR001",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "AKIR001"
}
] |
NCT04011293 | [
{
"id_field": "org_study_id",
"id_value": [
"HY001003"
]
}
] | https://clinicaltrials.gov/study/NCT04011293 | A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies | This is a single arm, open-label, single center study to determine the safety and efficacy of CNCT19 in adult patients with Relapsed or Refractory B cell Malignancies. | A Clinical Study of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory B Cell Malignancies | [
{
"description": "0.5 to 4 x 10^6 autologous CNCT19 transduced cells per kg body weight, with a maximum dose of 4 x 10^8 autologous CNCT19 transduced cells via intravenous infusion.",
"name": "CNCT19",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Single dose of CNCT19",
"design_group_title": "A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "0.5 to 4 x 10^6 autologous CNCT19 transduce... | [
"Relapsed or Refractory Hematological Malignancies"
] | [
"Shandong University"
] | [
"Juventas Cell Therapy Ltd."
] | [
[
{
"name": "纳基奥仑赛",
"lang": "CN"
},
{
"name": "Inaticabtagene Autoleucel",
"lang": "EN"
}
]
] | null |
NCT06067555 | [
{
"id_field": "org_study_id",
"id_value": [
"2000035891"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"2T32AR007016-47"
]
}
] | https://clinicaltrials.gov/study/NCT06067555 | Intradermal Influenza Vaccination | The goal of this study is to characterize the immune response, both innate and adaptive, as well as locally and systemic, to intradermal (ID) vaccination in healthy individuals. The intervention involves intradermal administration of an FDA-approved intramuscular seasonal influenza vaccine, using an FDA-approved device... | Characterization of Immune Response to Intradermal Influenza Vaccination | [
{
"description": "MicronJet 600 syringe will be used to administer intradermal flu vaccine injections",
"name": "MicronJet",
"normalized_type": "63bce838d71c4229808b289e8cf3172d",
"type": "Device"
},
{
"description": "Intradermal injections of 0.3mL",
"name": "Fluzone® Quadrivalent",
... | [
{
"design_group_description": "An intramuscular control group, from which no skin biopsies will be taken after vaccination. Only the intramuscular cohort will receive the flu vaccine via standard IM route in the deltoid region of the upper arm.",
"design_group_title": "Intramuscular (IM) Control",
"desi... | [
"Vaccine Reaction"
] | [
"Yale University"
] | [
"The University of Chicago",
"Silicon Valley Community Foundation"
] | [
[
{
"name": "四价流感病毒裂解疫苗(Sanofi)",
"lang": "CN"
},
{
"name": "Tetravalent influenza vaccine(Split, inactivated)(Sanofi)",
"lang": "EN"
}
]
] | null |
NCT02210117 | [
{
"id_field": "org_study_id",
"id_value": [
"2013-0715"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2014-01857"
]
},
{
"id_domain": "M D Anderson Cancer Center"... | https://clinicaltrials.gov/study/NCT02210117 | Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery | This randomized pilot early phase I trial studies the side effects and how well nivolumab alone works compared to nivolumab with bevacizumab or ipilimumab before surgery in treating patients with kidney cancer, also referred to as renal cell cancer, that has spread to another place in body and can be removed by surgery... | A Pilot Randomized Tissue-Based Study Evaluating Anti-PD1 Antibody or Anti-PD1 + Bevacizumab or Anti-PD1 + Anti-CTLA-4 in Patients With Metastatic Renal Cell Carcinoma Who Are Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment Biopsy | [
{
"description": "Given IV",
"name": "Bevacizumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Anti-VEGF",
"Anti-VEGF Humanized Monoclonal Antibody",
"Anti-VEGF rhuMAb",
"Avastin",
"BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED",
"Bevacizuma... | [
{
"design_group_description": "Patients receive nivolumab IV over 60 minutes on day 1 every 2 weeks for 6 weeks. Approximately 4 weeks later, patients undergo nephrectomy, metastasectomy or biopsy.<br/>Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even sl... | [
"Clear Cell Renal Cell Carcinoma",
"Metastatic Kidney Carcinoma",
"Stage IV Renal Cell Cancer AJCC v7"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "伊匹木单抗",
"lang": "CN"
},
{
"name": "Ipilimumab",
"lang": "EN"
},
{
"name": "イピリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
... | null |
NCT02457975 | [
{
"id_field": "org_study_id",
"id_value": [
"PRO00024065"
]
},
{
"id_field": "acronym",
"id_value": [
"PTDME"
]
}
] | https://clinicaltrials.gov/study/NCT02457975 | Photobiomodulation for the Treatment of Diabetic Macular Edema | The current application proposes to conduct a prospective, clinical trial in diabetic subjects with diabetic macular edema (DME) to evaluate the therapeutic efficacy of 670 nm photobiomodulation on validated clinical outcome measures and anatomical changes in central macula by optical coherence tomography (OCT) and oth... | Near-Infrared Photobiomodulation for the Treatment of Diabetic Macular Edema | [
{
"description": "Battery operated, hand-held, 10 cm2 Light Emitting Diode (LED) array designed to deliver 50 mW/cm2 of light for 90 seconds resulting in a light dose of 4.5 Joules/cm2",
"name": "670nm PBM",
"normalized_type": "63bce838d71c4229808b289e8cf3172d",
"other_name": [
"WARP10 by Quan... | [
{
"design_group_description": "Three intravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be benefic... | [
"Diabetic Retinopathy"
] | [
"Medical College of Wisconsin"
] | [
"University of Wisconsin-Milwaukee"
] | [
[
{
"name": "阿柏西普",
"lang": "CN"
},
{
"name": "Aflibercept",
"lang": "EN"
},
{
"name": "アフリベルセプト（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "贝伐珠单抗",
"lang": "CN"
},
{
"name": "Bevacizumab",
"lang": "EN"
},
{
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PTDME"
}
] |
NCT04461457 | [
{
"id_field": "org_study_id",
"id_value": [
"001-211Astatine"
]
},
{
"id_domain": "Swedish Medical Products Agency (MPA)",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"151:2004/26262"
]
},
{
"id_domain": "Ethics committee, Sahlgren... | https://clinicaltrials.gov/study/NCT04461457 | Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2 | In this alpha-radioimmunotherapy study groups of 3 patients with recurring epithelial ovarian cancer treated by salvage chemo-therapy and being in complete or good partial remission will receive one intra peritoneal infusion of 211 astatine (211At)-MX35 F(ab')2 . Patients will receive a single dose of MX35 F(ab')2 radi... | Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2 | [
{
"description": "Alpha emitting radionuclide 211At conjugated to monoclonal antibody MX35 F(ab')2. Targeting the sodium phosphate transporter (NaPi2b).",
"name": "211-astatine MX35 F(ab')2",
"normalized_type": "26823d77f12d4744a960c336f01c2d6e",
"type": "Combination Product"
}
] | [
{
"design_group_description": "Four groups of 3 patients with recurring ovarian cancer treated by salvage chemo-therapy and being in complete or good partial remission will receive one IP dose of 211astatine-MX35 F(ab'2). Starting at 50 MBq/L. Dose escalation 100 Mbq/L, 200 MBq/L and finally 300 MBq/L.",
"d... | [
"Ovarian Cancer"
] | [
"Region Västra Götaland"
] | [
"Sahlgrenska Universitetssjukhuset",
"Vetenskapsrådet"
] | [
[
{
"name": "211-astatine-MX35 F(ab')2(Memorial Sloan-Kettering Cancer Center)",
"lang": "EN"
}
]
] | null |
NCT05516472 | [
{
"id_field": "org_study_id",
"id_value": [
"1051917"
]
},
{
"id_field": "acronym",
"id_value": [
"FMT IND"
]
}
] | https://clinicaltrials.gov/study/NCT05516472 | Fecal Microbiota Transplantation in Kidney Stone Patients | The purpose of this study is to measure the impact of Microbial Transplant Therapy (MTT) on 24-hour urine parameters in recurrent hypercalciuric and hyperoxaluric kidney stone formers. | Fecal Microbiota Transplantation (FMT CAPSULE DE, FMPCapDE, MTP-CP101) in Kidney Stone Patients (FMT IND STUDY) | [
{
"description": "Participants will take microbial capsules, 2 capsules daily for 7 days",
"name": "Microbial Transplant Therapy",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"fecal transplant"
],
"type": "Drug"
},
{
"description": "Participants will ... | [
{
"design_group_description": "Treatment group based on 24 hour urine analysis showing oxalate >40 mg/day.",
"design_group_title": "Hyperoxaluric group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Kidney Stones"
] | [
"Intermountain Health (Utah)"
] | [
"University of Minnesota"
] | [
[
{
"name": "Fecal Microbiota(Litholink)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "FMT IND"
}
] |
NCT04167761 | [
{
"id_field": "org_study_id",
"id_value": [
"52647"
]
}
] | https://clinicaltrials.gov/study/NCT04167761 | Ertugliflozin: Cardioprotective Effects on Epicardial Fat | The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation. | Ertugliflozin: Cardioprotective Effects on Epicardial Fat | [
{
"description": "Adipose tissue samples collected from participants were treated with Ertugliflozin at a concentration of 25 µM in vitro. This treatment was applied in a laboratory setting to assess the effects of Ertugliflozin on lipolysis, inflammatory cytokine release, and gene expression in epicardial, per... | [
{
"design_group_description": "Adipose tissue samples collected from participants were treated with Ertugliflozin at a concentration of 25 µM in vitro. Tissue samples were incubated with Ertugliflozin to evaluate its effects on lipolysis, inflammation, and gene expression in epicardial, pericardial, and subcuta... | [
"Cardiovascular Diseases",
"Atherosclerosis",
"Type 2 Diabetes",
"Insulin Resistance"
] | [
"Stanford University"
] | [
"Merck Sharp & Dohme Corp."
] | [
[
{
"name": "艾托格列净",
"lang": "CN"
},
{
"name": "Ertugliflozin pidolate",
"lang": "EN"
}
]
] | null |
NCT07358234 | [
{
"id_field": "org_study_id",
"id_value": [
"25-005776"
]
},
{
"id_field": "secondary_id",
"id_value": [
"25-005776"
]
}
] | https://clinicaltrials.gov/study/NCT07358234 | Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis. | The purpose of this study is to compare Eosinophilic Esophagitis treatments Eohilia with Dupixent in their effects on diameter and scarring of the esophagus. | Prospective Trial Comparing Swallowed Topical Budesonide With Subcutaneous Dupilumab on Esophageal Diameter and Fibrotic Change in Eosinophilic Esophagitis | [
{
"description": "300 mg weekly injection",
"name": "Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "2mg twice daily",
"name": "budesonide oral suspension",
"normalized_type": "3d1aa88... | [
{
"design_group_description": "2mg twice daily",
"design_group_title": "budesonide oral suspension (Eohilia)",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "2mg twice... | [
"Eosinophilic Esophagitis (EoE)"
] | [
"Mayo Clinic"
] | [
"Vanderbilt University Medical Center"
] | [
[
{
"name": "度普利尤单抗",
"lang": "CN"
},
{
"name": "Dupilumab",
"lang": "EN"
},
{
"name": "デュピルマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "布地奈德",
"lang": "CN"
},
{
"name": "Budesonide",
"lang": "EN"
},
{
"... | null |
NCT07420530 | [
{
"id_field": "org_study_id",
"id_value": [
"29009"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DC023381"
]
},
{
"id_field": "acronym",
"id_value": [
"EILO"
]
},
{
"id_field": "secondary_id",
... | https://clinicaltrials.gov/study/NCT07420530 | Respiratory and Real-time Dynamics in Exercise-Induced Paradoxical Vocal Fold Motion | The overall objectives of the proposed research are to:<br/>1. Evaluate the diagnostic validity of a novel mechano-acoustic signatures of task-characteristic activity during symptomatic and asymptomatic breathing in Exercise-Induced Laryngeal Obstruction (EILO) patients with the use of a novel miniature, soft wearable ... | Respiratory and Real-time Dynamics in Exercise-Induced Paradoxical Vocal Fold Motion | [
{
"description": "Breathing Hypercapnic Gas (10% CO2 (carbon dioxide) and 21%O2 (oxygen), balance N210% (nitrogen))",
"name": "Carbon Dioxide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Random Assignment to breathing conditions (rest breathing... | [
{
"design_group_description": "Participants will breathe room air",
"design_group_title": "Control Arm",
"design_group_type": "No Intervention"
},
{
"design_group_description": "Participants will breathe Hypercapnic Gas (10% CO2 (carbon dioxide) and 21%O2 (oxygen), balance N210% (nitrogen)).",
... | [
"Exercise-Induced Vocal Cord Dysfunction",
"Paradoxical Vocal Fold Motion",
"Vocal Cord Dysfunction"
] | [
"Indiana University"
] | [
"National Jewish Health, Inc.",
"Purdue University",
"National Institute on Deafness & Other Communication Disorder",
"The Indiana University School of Medicine"
] | [
[
{
"name": "二氧化碳",
"lang": "CN"
},
{
"name": "Carbon Dioxide",
"lang": "EN"
},
{
"name": "二酸化炭素",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EILO"
}
] |
NCT07239895 | [
{
"id_field": "org_study_id",
"id_value": [
"BO-V1.2"
]
},
{
"id_field": "secondary_id",
"id_value": [
"BO-V1.2"
]
}
] | https://clinicaltrials.gov/study/NCT07239895 | Treatment of Pediatric Bronchiolitis Obliterans by Airway Basal Stem Cells | Bronchiolitis obliterans (BO) is a chronic lung disease which was initiated with injury of the bronchiolar epithelium and resulted in nonuniform luminal obliteration or narrowing. Among children, the most common form of BO is post-infectious BO with a lack of treatment guidelines or standard therapy. In this study, an ... | Exploratory Study of Airway Basal Stem Cells on Treatment of Pediatric Bronchiolitis Obliterans | [
{
"description": "Airway Basal Stem Cells",
"name": "Airway Basal Stem Cells",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_title": "Airway Basal Stem Cells",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Airway Basal Stem Cells",
"intervention_name": "Airway Basal Stem Cell... | [
"Pediatric Bronchiolitis Obliterans"
] | [
"Regend Therapeutics Co. Ltd."
] | [
"Shanghai Children's Hospital"
] | [
[
{
"name": "Airway Basal Stem Cells(Regend Therapeutics)",
"lang": "EN"
}
]
] | null |
NCT06110208 | [
{
"id_field": "org_study_id",
"id_value": [
"GC12-132"
]
}
] | https://clinicaltrials.gov/study/NCT06110208 | Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML | This study is a single-center clinical study. The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects . The included population were patients with relapsed and refractory acute myeloid leukemia (r/r AML) . | Clinical Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T Injection in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia | [
{
"description": "CLL1 and CD38 dual-target CAR-T injection",
"name": "CLL1 and CD38 dual-target CAR-T injection",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "This study is a single-center clinical study. The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects . The included population was patients with relapsed and refractory acute myeloid leuke... | [
"Acute Myeloid Leukemia"
] | [
"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China"
] | [
"Gracell Biotechnologies (Shanghai) Co., Ltd."
] | [
[
{
"name": "CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai)",
"lang": "EN"
}
]
] | null |
NCT06205342 | [
{
"id_field": "org_study_id",
"id_value": [
"PRO 00132905"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1UG3DK136705-01"
]
},
{
"id_field": "acronym",
"id_value": [
"STEMCAP-1"
]
}
] | https://clinicaltrials.gov/study/NCT06205342 | Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain | This protocol aims to test whether an infusion of allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) can reduce pain associated with chronic pancreatitis (CP) and explore potential mechanisms of MSC action. | STEMCAP-1: Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain | [
{
"description": "Autologous bone marrow derived MSCs",
"name": "Mesenchymal Stem Cells",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"MSCs"
],
"type": "Drug"
},
{
"description": "Control",
"name": "Other: Placebo",
"normalized_type": "ffd65a2... | [
{
"design_group_description": "MSC",
"design_group_title": "Experimental Cohort",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Autologous bone marrow derived MSCs",
... | [
"Chronic Pancreatitis",
"Chronic Pain"
] | [
"The Medical University of South Carolina"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases"
] | [
[
{
"name": "Autologous Bone Marrow Derived Mesenchymal Stem Cells(Medical University of South Carolina)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "STEMCAP-1"
}
] |
NCT06045091 | [
{
"id_field": "org_study_id",
"id_value": [
"HRAIN01-MM04-POC"
]
}
] | https://clinicaltrials.gov/study/NCT06045091 | To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL | This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human BCMA targeted CAR-NK Cells injection, and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory multiple myeloma or plasm... | A Early Phase 1 Clinical Trial to Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | [
{
"description": "Allogenic genetically modified anti-BCMA CAR transduced NK cells",
"name": "Human BCMA targeted CAR-NK cells injection",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"BCMA CAR-NK"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Two doses on Day 0 and Day 7. 1.5×10^8 CAR+NK cells/dose, 3.0×10^8 CAR+NK cells/dose or 6.0×10^8 CAR+NK cells/dose",
"design_group_title": "Human BCMA Targeted CAR-NK Cells Injection",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562... | [
"Multiple Myeloma",
"Plasma Cell Leukemia"
] | [
"Hrain Biotechnology Co., Ltd."
] | [
"Shanghai Changzheng Hospital"
] | [
[
{
"name": "HR-012",
"lang": "EN"
}
]
] | null |
NCT06788431 | [
{
"id_field": "org_study_id",
"id_value": [
"IMC-001-01"
]
}
] | https://clinicaltrials.gov/study/NCT06788431 | A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome. | A two-center, randomized, double-blind, placebo-controlled, dose-escalation IIT clinical study evaluating the safety and preliminary efficacy of injectable IMC-001 in improving atherosclerotic plaque stability in patients with acute coronary syndrome. The plan is to conduct 2 dose groups, with 9 subjects enrolled in ea... | A Two-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Investigator-Initiated Trial (IIT) Evaluating the Safety and Preliminary Efficacy of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome. | [
{
"description": "Subjects receive IMC-001 administered by injection and also receive optimal medical treatment.",
"name": "IMC-001 and Optimal medical treatment",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Subjects receive IMC-001 placebo admi... | [
{
"design_group_title": "IMC-001 and Optimal medical treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Subjects receive IMC-001 administered by injection and also rece... | [
"Atherosclerosis"
] | [
"ImmuneOnco Biopharmaceuticals (Shanghai), Inc."
] | [
"ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.",
"The First Affiliated Hospital of Nanyang Medical College"
] | [
[
{
"name": "替达派西普",
"lang": "CN"
},
{
"name": "Timdarpacept",
"lang": "EN"
}
]
] | null |
NCT04495920 | [
{
"id_field": "org_study_id",
"id_value": [
"2005367-150"
]
}
] | https://clinicaltrials.gov/study/NCT04495920 | Clinical Evaluation of the Residual Antimicrobial Activity | The purpose of this study is to evaluate the residual antimicrobial efficacy of one test product as defined by the difference between the number of a challenge bacterial species recovered following exposure to the test product and the number recovered when untreated (negative control). The challenge bacterial species t... | Clinical Evaluation of the Residual Antimicrobial Activity of One Test Product Based on the ASTM E2752 Test Method | [
{
"description": "Alcohol and choline geranate",
"name": "CGB-S-100",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"IonLAST gel (CGB-S-100 gel)"
],
"type": "Drug"
}
] | [
{
"design_group_title": "Test product",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Alcohol and choline geranate",
"intervention_name": "CGB-S-100",
"interve... | [
"Bacterial Overgrowth"
] | [
"CAGE Bio, Inc."
] | [
"Nelson Laboratories Bozeman LLC"
] | [
[
{
"name": "CGB-S-100",
"lang": "EN"
}
]
] | null |
NCT04130152 | [
{
"id_field": "org_study_id",
"id_value": [
"SOLTI-1710"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2019-001275-36"
]
},
{
"id_field": "acronym",
"id_value": [
"PROMETEO II"
]
}
] | https://clinicaltrials.gov/study/NCT04130152 | Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy | PROMETEO II is a single-arm window of opportunity trial to evaluate biologic and anti-proliferative effects of palbociclib and letrozole in HR+/HER2-negative operable breast cancer (BC) patients with residual disease after neoadjuvant chemotherapy (NAC) and help to identify biomarkers for better patient selection. | Palbociclib in Combination With Letrozole in Patients With Hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor 2 (HER2) Negative Residual Disease After Standard Neoadjuvant Chemotherapy (PROMETEO II) | [
{
"description": "Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle",
"name": "Palbociclib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Ibrance"
],
"type": "Drug"
},
{
"description": "Letrozole: oral,... | [
{
"design_group_description": "Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.<br/>If the patient is pre-menopausal, ovarian suppression with luteinizing hormone-releasing hormone (LHRH) ana... | [
"Breast Cancer"
] | [
"Grupo SOLTI"
] | [
"Pfizer Inc."
] | [
[
{
"name": "来曲唑",
"lang": "CN"
},
{
"name": "Letrozole",
"lang": "EN"
},
{
"name": "レトロゾール",
"lang": "JP"
}
],
[
{
"name": "哌柏西利",
"lang": "CN"
},
{
"name": "Palbociclib",
"lang": "EN"
},
{
"name": "パル... | [
{
"identifier_source": [
{
"code": "23a885a0a9583a8aaa8539e30d33342d",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "SOLTI1710 PROMETEO II"
},
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
... |
NCT03910842 | [
{
"id_field": "org_study_id",
"id_value": [
"T2018-14"
]
}
] | https://clinicaltrials.gov/study/NCT03910842 | Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy | This is a single arm, open-label, early phase Ⅰ study, to determine the safety and efficacy of CD19-TriCAR-T and CD19-TriCAR-SILK cell therapy in Children CD19+ Leukemia Non-Hodgkin lymphoma treatment. | Adoptive Immunotherapy for Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell | [
{
"description": "A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.",
"name": "CD19-TriCAR-T/SILK",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
... | [
{
"design_group_description": "CD19-TriCAR-T/SILK cells will be administered intravenously",
"design_group_title": "CD19-TriCAR-T/NK（SILK）",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention... | [
"Non-Hodgkin Lymphoma of Intestine",
"Leukemia"
] | [
"Timmune"
] | [
"Hunan Provincial People's Hospital"
] | [
[
{
"name": "CD19-TriCAR SILK cell therapy (Timmune Biotech)",
"lang": "EN"
}
]
] | null |
NCT03684980 | [
{
"id_field": "org_study_id",
"id_value": [
"18-410"
]
}
] | https://clinicaltrials.gov/study/NCT03684980 | LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma | The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL. | LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma | [
{
"description": "(Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m^2 (Cohort E) will receive MTX ≤ 3.5 g/ m2",
"name": "Methotrexate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Patients will be treated with rituximab 500... | [
{
"design_group_description": "Patients will receive rituximab Day 1 (+/- 7 days) and MTX Day 2 (+/- 7 days) as per standard of care. Voraxaze will be administered each cycle 24 hours (+/- 2 h) after start of MTX infusion. Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8. ... | [
"Central Nervous System Lymphoma"
] | [
"Memorial Sloan Kettering Cancer Center"
] | [
"The University of Alabama at Birmingham"
] | [
[
{
"name": "羧肽酶",
"lang": "CN"
},
{
"name": "Glucarpidase",
"lang": "EN"
},
{
"name": "グルカルピダーゼ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "亚叶酸钙",
"lang": "CN"
},
{
"name": "Leucovorin Calcium",
"lang": "EN"
},
... | null |
NCT04587791 | [
{
"id_field": "org_study_id",
"id_value": [
"JD001"
]
},
{
"id_domain": "Yale HRPP",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"2000029286"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_valu... | https://clinicaltrials.gov/study/NCT04587791 | Cannabidiol in Opioid Use Disorder and Chronic Pain | This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of Cannabidiol (CBD) on measures of pain and opioid craving in outpatients with opioid use disorder (OUD) receiving medication-assisted treatment with methadone or buprenorphine. With a d... | Cannabidiol Pharmacotherapy for Co-occurring Opioid Use Disorder and Chronic Pain | [
{
"description": "Participants will receive 400 mg CBD",
"name": "400 mg Cannabidiol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CBD",
"Epidiolex"
],
"type": "Drug"
},
{
"description": "Participants will receive 800 mg CBD",
"name": "800 ... | [
{
"design_group_description": "CBD 400 mg",
"design_group_title": "CBD 400 mg",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Participants will receive 400 mg CBD",
... | [
"Chronic Pain",
"Opioid Use Disorder"
] | [
"Yale University"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "大麻二酚",
"lang": "CN"
},
{
"name": "Cannabidiol",
"lang": "EN"
}
]
] | null |
NCT05955885 | [
{
"id_field": "org_study_id",
"id_value": [
"25925"
]
}
] | https://clinicaltrials.gov/study/NCT05955885 | Effect of Over-the-counter NSAIDS on Cough Reflex Sensitivity in Patients with Upper Respiratory Tract Infections | The goal of this mechanism of disease study is to investigate the effect of flurbiprofen, a non-steroidal anti-inflammatory drug (NSAID), on the cough hypersensitivity associated with upper respiratory tract infections (URTI).<br/>The main questions it aims to answer are:<br/>* Q1: Does a single treatment with an appro... | Effect of Over-the-counter Non-steroidal Anti-inflammatory Treatments on Cough Reflex Sensitivity in Subjects with Upper Respiratory Tract Infection | [
{
"description": "This commercially available, over-the-counter lozenge manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years.",
"nam... | [
{
"design_group_description": "30 participants will be asked to suck one (1) flurbiprofen 8.75 mg honey and lemon lozenge (tradename: Strepfen) until dissolved.",
"design_group_title": "Flurbiprofen Oral Lozenge",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b3... | [
"Cough",
"Upper Respiratory Tract Infections"
] | [
"University of Melbourne"
] | [
"Reckitt Benckiser LLC"
] | [
[
{
"name": "氟比洛芬",
"lang": "CN"
},
{
"name": "Flurbiprofen",
"lang": "EN"
},
{
"name": "フルルビプロフェン",
"lang": "JP"
}
]
] | null |
NCT05715606 | [
{
"id_field": "org_study_id",
"id_value": [
"Meta10-19-001"
]
}
] | https://clinicaltrials.gov/study/NCT05715606 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research | A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research | [
{
"description": "Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion",
"name": "Metabolically Armed CD19 CAR-T cells",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Meta10-19"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. A dose of metabolically armed CD19 CAR-T cells will be infused on day 0.",
"design_group_title": "Administration of Metabolic... | [
"Diffuse Large B-cell Lymphoma"
] | [
"Anhui Provincial Hospital"
] | [
"Leman Biotech Co., Ltd."
] | [
[
{
"name": "Metabolically Armed CD19 CAR-T cells(Leman Biotech )",
"lang": "EN"
}
]
] | null |
NCT03771612 | [
{
"id_field": "org_study_id",
"id_value": [
"IDL"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R21AG058893-01A1"
]
}
] | https://clinicaltrials.gov/study/NCT03771612 | Inflammation and Daily Life Study | UCLA researchers looking for healthy individuals (age 45-60) to participate in a study investigating whether an anti-inflammatory medication can impact daily life experiences.<br/>Everyday for two weeks, participants will take either an anti-inflammatory medication (naproxen) twice daily, or a placebo pill twice daily.... | Inflammation and Daily Life Study | [
{
"description": "Half of the participants will be randomly assigned to receive naproxen twice daily (400 mg total daily; 200 mg 2x a day)",
"name": "Naproxen",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Half of the participants will be randoml... | [
{
"design_group_title": "Naproxen",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Half of the participants will be randomly assigned to receive naproxen twice daily (400 ... | [
"Inflammation"
] | [
"University of California, Los Angeles"
] | [
"National Institute on Aging"
] | [
[
{
"name": "萘普生",
"lang": "CN"
},
{
"name": "Naproxen",
"lang": "EN"
},
{
"name": "ナプロキセン",
"lang": "JP"
}
]
] | null |
NCT06171282 | [
{
"id_field": "org_study_id",
"id_value": [
"SHYY-R130-BSTT"
]
}
] | https://clinicaltrials.gov/study/NCT06171282 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors | 9 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced bone and soft tissue tumors. | A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors | [
{
"description": "R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11",
"name": "Recombinant oncolytic herpes simplex virus type Ⅰ (R130)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Oncolytic virus Inject... | [
{
"design_group_description": "Every 7-14 days,1-2 ml R130 （concentration of 1x10^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral in patients with relapsed/refractory bone and soft tissue tumors.",
"design_group_title": "Experimental: R130 Treatment Group",
"design_group_type": "Experimen... | [
"Osteosarcoma",
"Sarcoma",
"Soft Tissue Sarcoma",
"Bone Tumor"
] | [
"Shanghai Yunying Medical Technology Co., Ltd."
] | [
"Shanghai First People's Hospital"
] | [
[
{
"name": "Recombinant oncolytic herpes simplex virus type 1(Shanghai Yunying Medical Technology)",
"lang": "EN"
}
]
] | null |
NCT05871320 | [
{
"id_field": "org_study_id",
"id_value": [
"TECANT"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2019-003379-20"
]
},
{
"id_field": "acronym",
"id_value": [
"TECANT"
]
}
] | https://clinicaltrials.gov/study/NCT05871320 | Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms | The main goal of the study is to expand cancer preclinical research results on the usefulness of SSTR2-Antagonist [99mTc]Tc-TECANT1 in clinical practice. Detection of NEN and monitoring of response to therapy is still challenging due to their cellular heterogeneity. Initial preclinical studies suggest that NEN imaging ... | Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms - a Feasibility Study | [
{
"description": "only one arm - the administration of [99mTC]-Tc-TECANT1 in all patients included",
"name": "[99mTc]Tc-TECANT1",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | [
{
"design_group_description": "The injection volume will be up to 5 mL over 20 seconds with an activity of 10 MBq/kg body weight (range between min. 500 and max. 800 MBq). To ensure application of the complete activity additionally 10 mL of 0.9% saline will be infused via the same system.",
"design_group_ti... | [
"Neuroendocrine Tumors"
] | [
"Uniwersytet Jagiellonski"
] | [
"Medical University of Innsbruck",
"University of Ljubljana",
"UMC Ljubljana"
] | [
[
{
"name": "[99mTc]Tc-TECANT1",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "TECANT"
}
] |
NCT05105867 | [
{
"id_field": "org_study_id",
"id_value": [
"GC011-411"
]
}
] | https://clinicaltrials.gov/study/NCT05105867 | CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies | It is a single-arm, open-label clinical study to assess the safety and efficacy of the Anti-CD19 Universal CAR-T Cells injection for patients with CD19+ refractory/relapsed B cell acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. | A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Anti-CD19 Universal CAR-T Cells in the Treatment of CD19+ Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia and Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | [
{
"description": "Anti-CD19 Universal CAR-T Cells injection will be administered by vein after lymphodepletion.",
"name": "Anti-CD19 Universal CAR-T Cells injection",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Anti-CD19 Universal CAR-T Cells injection will be administered by vein after lymphodepletion .",
"design_group_title": "Anti-CD19 Universal CAR-T Cells injection",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5... | [
"Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia",
"Relapsed or Refractory B-cell Non-hodgkin Lymphoma"
] | [
"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China"
] | [
"Gracell Biotechnologies (Shanghai) Co., Ltd."
] | [
[
{
"name": "GC007g",
"lang": "EN"
}
]
] | null |
NCT01672255 | [
{
"id_field": "org_study_id",
"id_value": [
"HP-00044537; SSRI and Exercise"
]
}
] | https://clinicaltrials.gov/study/NCT01672255 | Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM) | Exercise is a cornerstone of diabetes management. It helps reduce blood pressure, promote weight loss, lower insulin resistance and improve glucose and lipid (triglyceride and HDL-cholesterol) profiles. Unfortunately, the benefits of exercise are often not embraced by diabetic individuals because of the fear of low blo... | Hypoglycemia Associated Autonomic Failure in Type 1 DM, SSRI and Exercise | [
{
"description": "20 mg week 1, 40 mg week 2, 60 mg week 3, 80 mg week 4-6",
"name": "Fluoxetine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Prozac"
],
"type": "Drug"
},
{
"description": "20 mg Week 1, 40 mg Week 2, 60 mg Week 3, 80 mg Week 4-6",
... | [
{
"design_group_description": "90 minute exercise baseline with 6 weeks treatment with SSRI (Prozac). Repeat 90 minute exercise after 6 week treatment.",
"design_group_title": "Trial 1-SSRI",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76a... | [
"Type 1 Diabetes",
"Hypoglycemia Associated Autonomic Failure"
] | [
"University of Maryland Baltimore"
] | [
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "盐酸氟西汀",
"lang": "CN"
},
{
"name": "Fluoxetine Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT02728830 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro00068544"
]
}
] | https://clinicaltrials.gov/study/NCT02728830 | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | The ultimate goal of the study is to identify potential biomarkers, immune gene expression signatures, and co-stimulatory pathways that may be used to understand the effect of immune checkpoint inhibitors on gynecologic cancers. | A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers of Mullerian Origin | [
{
"description": "Pembrolizumab 200mg IV",
"name": "Pembrolizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Keytruda"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Subjects will receive one dose of 200mg pembrolizumab by IV 14-21 days prior to surgery. Subjects will undergo standard surgical cytoreductive surgery as deemed appropriate by their gynecologic oncologist, followed by standard adjuvant chemotherapy for their cancer as deemed appro... | [
"Gynecologic Neoplasms",
"Epithelial Ovarian Cancer",
"Uterine Endometrial Cancer",
"Fallopian Tube Cancer",
"Peritoneal Cancer"
] | [
"Duke University"
] | [
"Merck Sharp & Dohme Corp."
] | [
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name": "ペムブロリズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT00879164 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000640197"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA015083"
]
},
{
"id_domain": "Mayo Clinic Cancer Center",
"id_field": "secondary_id",
"id_type": "Other ... | https://clinicaltrials.gov/study/NCT00879164 | Stellate Ganglion Nerve Block in Treating Women With Hot Flashes | RATIONALE: A stellate ganglion nerve block may help relieve hot flashes in women.<br/>PURPOSE: This clinical trial is studying how well a stellate ganglion nerve block works in treating women with hot flashes. | Pilot Evaluation of a Stellate Ganglion Block for the Treatment of Hot Flashes | [
{
"name": "bupivacaine hydrochloride",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "questionnaire administration",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"type": "Other"
}
] | null | [
"Hot Flashes"
] | [
"Mayo Clinic"
] | [
"National Cancer Institute"
] | [
[
{
"name": "盐酸布比卡因",
"lang": "CN"
},
{
"name": "Bupivacaine Hydrochloride",
"lang": "EN"
},
{
"name": "ブピバカイン塩酸塩水和物",
"lang": "JP"
}
]
] | null |
NCT04050410 | [
{
"id_field": "org_study_id",
"id_value": [
"VANDERBILT_IRB_190703"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R56HL142583"
]
}
] | https://clinicaltrials.gov/study/NCT04050410 | Autonomic Determinants of POTS - Pilot1 | Postural tachycardia syndrome (POTS) is a relatively common condition affecting mostly otherwise healthy young women. It is the cause of significant disability and an impairment in quality of life. These patients have high heart rate and symptoms during standing. Many of these patients are disabled and have a poor qual... | Autonomic Determinants of Postural Tachycardia Syndrome (Acute Pilot Study 1) | [
{
"description": "active drug given as 1 dose",
"name": "Moxonidine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Physiotens"
],
"type": "Drug"
},
{
"description": "placebo pill given as 1 dose",
"name": "Placebo",
"normalized_type": "3d1aa88... | [
{
"design_group_description": "Patients will receive a single oral dose of moxonidine 0.4 mg.",
"design_group_title": "Moxonidine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descript... | [
"Postural Tachycardia Syndrome"
] | [
"Vanderbilt University Medical Center"
] | [
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "盐酸莫索尼定",
"lang": "CN"
},
{
"name": "Moxonidine",
"lang": "EN"
}
]
] | null |
NCT06579430 | [
{
"id_field": "org_study_id",
"id_value": [
"201900307"
]
},
{
"id_field": "acronym",
"id_value": [
"Pre-CLOVER"
]
}
] | https://clinicaltrials.gov/study/NCT06579430 | Diagnostic Accuracy Study of Indocyanine Green for Perfusion Assessment | Background Near-infrared fluorescence guided surgery with indocyanine green (ICG) was introduced for parathyroid perfusion assessment during total thyroidectomy in 2016. ICG can visualize tissue perfusion, since it becomes completely and permanently fixed to plasma proteins in the bloodstream, and circulates in the int... | Diagnostic Accuracy Study of Indocyanine Green for Perfusion Assessment | [
{
"description": "ICG-NIRF was performed using the Quest Spectrum Platform 2.0. The camera lens was positioned at a fixed distance of 30 cm to the wound bed, at a perpendicular angle, with the gain set at 22.5 decibels (dB) and an exposure time of 50 milliseconds (ms). ICG was dissolved in sterile water at a co... | [
{
"design_group_description": "Patients undergoing total thyroidectomy are included in this arm. Patients are included in the University Medical Center Groningen and the Erasmus Medical Center Rotterdam. After total thyroidectomy, the perfusion in the parathyroid glands is imaged utilizing ICG-NIRF. Postoperati... | [
"Hypoparathyroidism"
] | [
"Universitair Medisch Centrum Groningen"
] | [
"Erasmus Medical Center (Private Equity)",
"Leids Universitair Medisch Centrum"
] | [
[
{
"name": "吲哚菁绿",
"lang": "CN"
},
{
"name": "Indocyanine Green",
"lang": "EN"
},
{
"name": "インドシアニングリーン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Pre-CLOVER"
}
] |
NCT05672342 | [
{
"id_field": "org_study_id",
"id_value": [
"22339"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2022-10253"
]
},
{
"id_domain": "City of Hope Comprehensive Canc... | https://clinicaltrials.gov/study/NCT05672342 | Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors | This clinical trial tests how well phytocannabinoids (cannabidiol [CBD] and tetrahydrocannbinol [THC]) work in reducing chronic chemotherapy-induced peripheral neuropathy (CIPN) in breast and colon cancer survivors. Neuropathy is the most common neurological symptom reported by cancer patients due to treatment. A varie... | A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy | [
{
"description": "Given PO",
"name": "Cannabidiol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CBD",
"CBD Oil",
"Epidiolex",
"GWP42003-P"
],
"type": "Drug"
},
{
"description": "Given PO",
"name": "Delta-8-Tetrahydrocannabinol",... | [
{
"design_group_description": "Patients receive CBD PO on study.",
"design_group_title": "Arm I (CBD)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Given PO",
"i... | [
"Breast Carcinoma",
"Chemotherapy-Induced Peripheral Neuropathy",
"Colon Carcinoma"
] | [
"City of Hope National Medical Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "大麻二酚",
"lang": "CN"
},
{
"name": "Cannabidiol",
"lang": "EN"
}
],
[
{
"name": "Delta-8-THC",
"lang": "EN"
}
]
] | null |
NCT04040465 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB_00117303"
]
}
] | https://clinicaltrials.gov/study/NCT04040465 | Asprin Dosing Estimator in Healthy Adults | Understanding sources of variability in human drug dosing is important to the beneficial and safe use of any drug. Understanding and applying the science of individualizing a drug dose to a patient is called precision medicine.<br/>Aspirin is one of the oldest most utilized medications for its ability to lower fever, r... | Asprin Dosing Estimator in Healthy Adults | [
{
"description": "Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.",
"name": "Aspirin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks",
"design_group_title": "Normal Weight/Low Dose Aspirin",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
... | [
"Aspirin Sensitivity"
] | [
"University of Utah"
] | [
"University of Colorado Denver"
] | [
[
{
"name": "阿司匹林",
"lang": "CN"
},
{
"name": "Aspirin",
"lang": "EN"
},
{
"name": "サリチル酸",
"lang": "JP"
}
]
] | null |
NCT05076513 | [
{
"id_field": "org_study_id",
"id_value": [
"2021-13"
]
},
{
"id_field": "secondary_id",
"id_value": [
"2021-13"
]
}
] | https://clinicaltrials.gov/study/NCT05076513 | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | This is an open-label, multi-center Phase 0 study with an expansion phase that will enroll up to 24 participants with newly-diagnosed glioblastoma and up to 18 recurrent glioma participants with IDH mutation and ATRX loss. The trial will be composed of a Phase 0 component (subdivided into Arm A and B) and a therapeutic... | A Phase 0 'Trigger' Trial of Niraparib in Newly-diagnosed Glioblastoma and Recurrent IDH1/2(+) ATRX Mutant Glioma | [
{
"description": "In Phase 0, 300mg administered orally QD for 4 days prior to resection.<br/>In the Expansion cohort/Maintenance phase, niraparib will be administered as described below:<br/>* For patients weighing <77 kg (<170 lbs) OR with a platelet count <150,000/mcL, the recommended dosage is 200 mg taken ... | [
{
"design_group_description": "Participants undergoing resection for a presumed newly-diagnosed glioblastoma (WHO grade 4) will be treated with niraparib for 4 days prior to surgical resection. Participants who proceed to the therapeutic expansion phase of this study will receive niraparib in combination with r... | [
"Glioblastoma",
"Glioblastoma Multiforme",
"Glioma",
"GBM",
"Glioma, Malignant",
"Glioblastoma Multiforme of Brain"
] | [
"St. Joseph's Medical Center, Inc."
] | [
"The University of California, San Francisco",
"Barrow Neurological Institute",
"GSK Plc"
] | [
[
{
"name": "甲苯磺酸尼拉帕利",
"lang": "CN"
},
{
"name": "Niraparib Tosylate",
"lang": "EN"
},
{
"name": "ニラパリブトシル酸塩水和物",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "a28a254eee5a2230d924888a0922a58e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "BIOM-06"
}
] |
NCT05280782 | [
{
"id_field": "org_study_id",
"id_value": [
"202107042"
]
},
{
"id_domain": "U.S. Food and Drug Administration",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"IND 157468"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH G... | https://clinicaltrials.gov/study/NCT05280782 | Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging-Dosimetry Group | This study is a single center, early phase 1 clinical imaging study designed to assess the dosimetry of 68Ga-Galmydar for PET/CT imaging. | Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging | [
{
"description": "Single intravenous injection of the PET radiotracer 68Ga-Galmydar.",
"name": "Ga-68 Galmydar",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"IND 157468"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Normal Volunteers will receive a single intravenous injection of 8 mCi ± 20% (6.4-9.6 mCi) of the PET radiotracer 68Ga-Galmydar. They will undergo whole-body PET/CT imaging at three-time points, immediately post [68Ga]Galmydar injection, and at 2 hours and 4 hours after injection.... | [
"Coronary Artery Disease"
] | [
"Washington University School of Medicine"
] | [
"National Heart, Lung & Blood Institute",
"National Institutes of Health"
] | [
[
{
"name": "Ga-68 Galmydar",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "a50a2393530a38e4945e048e238a83a3",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "GALMYDAR"
}
] |
NCT04231435 | [
{
"id_field": "org_study_id",
"id_value": [
"FEDR-CP-003"
]
},
{
"id_domain": "WHO",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"U1111-1245-6233"
]
}
] | https://clinicaltrials.gov/study/NCT04231435 | Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin | This is a nonrandomized, fixed-sequence, open-label study to evaluate the effect of a single dose of fedratinib on the PK, safety, and tolerability of single doses of digoxin, rosuvastatin, and metformin in healthy subjects. The subjects will participate as follows:<br/>* Screening phase<br/>* Treatment phase (includes... | A Phase 1, Open-label Study to Evaluate the Influence of Fedratinib on the Pharmacokinetics of Transporter Probe Substrates (Digoxin, Rosuvastatin, and Metformin) in Healthy Adult Subjects | [
{
"description": "Oral",
"name": "Fedratinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Oral",
"name": "Digoxin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Oral",
"name"... | [
{
"design_group_description": "All subjects will receive the following oral doses of IP following an overnight fast in the fixed-sequence below:<br/>* Day 1 (Period 1): 1 × 0.25-mg digoxin tablet, 1 × 10-mg rosuvastatin tablet, and 1 × 1000-mg metformin tablet.<br/>* Day 7 (Period 2): 6 × 100-mg fedratinib caps... | [
"Healthy Volunteers"
] | [
"Celgene Corp."
] | [
"Impact Biomedicines, Inc."
] | [
[
{
"name": "瑞舒伐他汀钙",
"lang": "CN"
},
{
"name": "Rosuvastatin Calcium",
"lang": "EN"
},
{
"name": "ロスバスタチンカルシウム",
"lang": "JP"
}
],
[
{
"name": "菲卓替尼",
"lang": "CN"
},
{
"name": "Fedratinib Hydrochloride",
"lang": "E... | null |
NCT07283094 | [
{
"id_field": "org_study_id",
"id_value": [
"2025-16661"
]
},
{
"id_domain": "Foghorn Therapeutics",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"2516661-FHD-286"
]
},
{
"id_field": "acronym",
"id_value": [
"FHD... | https://clinicaltrials.gov/study/NCT07283094 | FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia | This is a Phase 1, uncontrolled, single-arm, open-label, nonrandomized, dose escalation, study of Decitabine (DAC)+Venetoclax (VEN)+FHD-286 in participants with newly diagnosed Acute Myeloid Leukemia (AML) classified as adverse risk per the 2022 European Leukemia Net (ELN) criteria or AML that has progressed after one ... | FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia | [
{
"description": "Decitabine: 0.2 mg/kg/day subcutaneously once weekly (QW) (days 1, 8, 15, 22 [±3 days] of each 28-day cycle)<br/>- A second weekly dose may be added if the investigator determines that more rapid debulking is required for a participant with high disease burden. The 2 weekly DAC doses should, p... | [
{
"design_group_description": "Administration:<br/>* Decitabine is reconstituted with 5 mL of sterile water and given by subcutaneous (SC) injection at the investigational site.<br/>* Venetoclax is taken as a tablet provided by the investigational site pharmacy or another authorized specialty pharmacy.<br/>* FH... | [
"Acute Myeloid Leukemia",
"Myelodysplastic Syndrome"
] | [
"Montefiore Medical Center"
] | [
"Foghorn Therapeutics, Inc."
] | [
[
{
"name": "Camibirstat",
"lang": "EN"
}
],
[
{
"name": "维奈克拉",
"lang": "CN"
},
{
"name": "Venetoclax",
"lang": "EN"
},
{
"name": "ベネトクラクス",
"lang": "JP"
}
],
[
{
"name": "地西他滨",
"lang": "CN"
},
{
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "FHD-286"
}
] |
NCT05497778 | [
{
"id_field": "org_study_id",
"id_value": [
"2022-0130"
]
},
{
"id_domain": "NCI-CTRP Clinical Trials Registry",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"NCI-2022-06636"
]
}
] | https://clinicaltrials.gov/study/NCT05497778 | A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. | To learn if adding a new medication, IM156, to treatment with gemcitabine and nab-paclitaxel is safe and tolerable. The ability of this combination to improve the success of this treatment for these patients will also be studied. | A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. | [
{
"description": "Given by IV (vein)",
"name": "Gemcitabine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Gemcitabine Hydrochloride",
"Gemzar®"
],
"type": "Drug"
},
{
"description": "Given by IV (vein)",
"name": "Nab paclitaxel",
"norm... | [
{
"design_group_description": "In the Dose Escalation Phase of the study, we will identify the RPD2 of IM156. Subsequently, we will evaluate IM156 at the RP2D (established in the Dose Expansion Phase) and gemcitabine + nab-paclitaxel in the Dose Expansion Phase.",
"design_group_title": "Dose Escalation Phas... | [
"Pancreas Cancer"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "白蛋白结合型紫杉醇",
"lang": "CN"
},
{
"name": "Albumin-Bound Paclitaxel",
"lang": "EN"
},
{
"name": "パクリタキセル(JAN)",
"lang": "JP"
}
],
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
... | [
{
"identifier_source": [
{
"code": "d253e028045e5ed08d5a05a292428328",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "COMBAT-PC"
}
] |
NCT02655458 | [
{
"id_field": "org_study_id",
"id_value": [
"GCO 15-1275"
]
}
] | https://clinicaltrials.gov/study/NCT02655458 | Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | The purpose of this study is to explore the combination of Elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance to see what side effects it may have and how well it works for the treatment of symptomatic multiple myeloma diagnosed and treated with induction therapy in the pas... | Phase 1 Study of Elotuzumab in Combination With Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma | [
{
"description": "The following must also be administered before any elotuzumab:<br/>Dexamethasone 8 mg IV (on the day of elotuzumab infusion 45-90 mins prior to the start of infusion), the following 30 - 90 minutes prior to start of infusion: H1 blocker: diphenhydramine (25 - 50 mg po or IV) or equivalent, H2 ... | [
{
"design_group_description": "Max number of cycles is 12. Elotuzumab will be administered IV 20 mg/kg on Day 1 of each cycle. Lenalidomide dosing will start with cycle 4 at 10 mg orally daily days 1-21.",
"design_group_title": "autologous PBMC reconstitution, Elotuzumab, Lenalidomide",
"design_group_ty... | [
"Multiple Myeloma"
] | [
"Icahn School of Medicine at Mount Sinai"
] | [
"Bristol Myers Squibb Co."
] | [
[
{
"name": "来那度胺",
"lang": "CN"
},
{
"name": "Lenalidomide",
"lang": "EN"
},
{
"name": "レナリドミド水和物",
"lang": "JP"
}
],
[
{
"name": "埃罗妥珠单抗",
"lang": "CN"
},
{
"name": "Elotuzumab",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "4ad848a240e4a85a580ee8350425230d",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma"
}
] |
NCT02876510 | [
{
"id_field": "org_study_id",
"id_value": [
"IMA101-101"
]
},
{
"id_field": "acronym",
"id_value": [
"ACTolog"
]
}
] | https://clinicaltrials.gov/study/NCT02876510 | ACTolog in Patients With Solid Cancers | The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets. | Phase I Adoptive Cellular Therapy Trial With Endogenous CD8+ T Cells (ACTolog® IMA101) Alone or in Combination With Atezolizumab in Patients With Relapsed and/or Refractory Solid Cancers | [
{
"description": "Fludarabine infusion",
"name": "Fludarabine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Fludarabine monophosphate"
],
"type": "Drug"
},
{
"description": "Cyclophosphamide infusion",
"name": "Cyclophosphamide",
"normalized_... | [
{
"design_group_description": "* Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide<br/>* Infusion of the IMA101 T-cell product(s)<br/>* Post-infusion administration of low-dose recombinant human interleukin-2",
"design_group_title": "IMA101 product only (Cohort 1)",
... | [
"Cancer",
"Solid Tumor"
] | [
"Immatics US, Inc."
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang": "JP"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
... | [
{
"identifier_source": [
{
"code": "202ae949e42de4580488aa88055e2a5d",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "IMA101"
},
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
... |
NCT01032148 | [
{
"id_field": "org_study_id",
"id_value": [
"RPCI I 147408"
]
}
] | https://clinicaltrials.gov/study/NCT01032148 | Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma | The purpose of this study is to find out the effects of a drug called LBH589 when given to people with recurrent or refractory Hodgkin or Non-Hodgkin's lymphoma. The safety of this drug will also be studied. The participants' physical state, changes in the size of the tumor, or state of Hodgkin or non-Hodgkin's Lymphom... | Phase I Study of LBH589, A Novel Oral Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma | [
{
"description": "LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.",
"name": "LBH589",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "LBH589 administered orally as once daily dose of 20 mg po q M, W, F on a q 28 day cycle, escalating to a maximum dase of 60 mg",
"design_group_title": "LBH589",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
... | [
"Hodgkin's Lymphoma",
"Non-Hodgkin's Lymphoma"
] | [
"Roswell Park Comprehensive Cancer Center"
] | [
"Novartis AG"
] | [
[
{
"name": "乳酸帕比司他",
"lang": "CN"
},
{
"name": "Panobinostat lactate",
"lang": "EN"
},
{
"name": "パノビノスタット乳酸塩",
"lang": "JP"
}
]
] | null |
NCT06329206 | [
{
"id_field": "org_study_id",
"id_value": [
"GH2616-101"
]
}
] | https://clinicaltrials.gov/study/NCT06329206 | A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors | This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics (PD) and preliminary efficacy of GH2616 Tablet in subjects with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib). | A Phase Ia/Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of GH2616 Tablet in Subjects With Advanced Solid Tumors | [
{
"description": "GH2616 tablets will be given orally",
"name": "GH2616 Tablets",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Dose Escalation: Dose Escalation Cohorts Subjects will be enrolled at various doses of GH2616. These Dose Escalation Cohorts will be utilized to To determine the maximum tolerated dose (MTD) and/or recommended dose for expansion(s) (RDEs) for Dose Expansion. Dose Escalation: Backf... | [
"Advanced Solid Tumors"
] | [
"Suzhou Genhouse Bio Co., Ltd."
] | [
"The First Affiliated Hospital of Zhengzhou University",
"Zhejiang Cancer Hospital",
"Henan Cancer Hospital",
"Hubei Cancer Hospital"
] | [
[
{
"name": "GH-2616",
"lang": "EN"
}
]
] | null |
NCT04405167 | [
{
"id_field": "org_study_id",
"id_value": [
"842603, UPCC 45419"
]
},
{
"id_domain": "University of Pennsylvania",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"UPCC 45419"
]
}
] | https://clinicaltrials.gov/study/NCT04405167 | Tasquinimod for the Treatment of Relapsed or Refractory Myeloma | This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma. | Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refractory Myeloma | [
{
"description": "Tasquinimod will be supplied as oral capsules.",
"name": "Tasquinimod",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone",
"name": "IRd chemotherapy",
"normaliz... | [
{
"design_group_description": "There are up to 5 planned dose levels, with 3 de-escalation dose levels available in case dose level 1 is determined to exceed the MTD. This arm will enroll 15-30 subjects if all dose levels are explored.",
"design_group_title": "A1: Tasquinimod single agent dose escalation",
... | [
"Multiple Myeloma"
] | [
"University of Pennsylvania"
] | [
"Active Biotech AB"
] | [
[
{
"name": "他喹莫德",
"lang": "CN"
},
{
"name": "Tasquinimod",
"lang": "EN"
}
]
] | null |
NCT02609477 | [
{
"id_field": "org_study_id",
"id_value": [
"6002-017"
]
}
] | https://clinicaltrials.gov/study/NCT02609477 | A Study to Evaluate Abuse Potential of Istradefylline | This study is to evaluate the abuse potential of single-doses of istradefylline compared to placebo and phentermine in recreational stimulant users. Subjects will participate in an outpatient medical Screening visit, a 5-day Qualification (Drug Discrimination) Phase, a 6-period Treatment Phase, and an outpatient safety... | A Double-Blind, Randomized, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Istradefylline in Recreational Drug Users | [
{
"description": "Istradefylline 40, 80, 160 mg",
"name": "Istradefylline",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"6002"
],
"type": "Drug"
},
{
"description": "Phentermine 45 or 90 mg",
"name": "Phentermine 45 mg",
"normalized_type": "3d... | [
{
"design_group_description": "40 mg istradefylline (1 × 40 mg tablet + 3 × placebo tablets + 3 × placebo capsules)",
"design_group_title": "Istradefylline 40 mg",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Drug Abuse"
] | [
"Kyowa Kirin Co., Ltd."
] | [
"Kyowa Hakko Kirin Pharma, Inc."
] | [
[
{
"name": "伊曲茶碱",
"lang": "CN"
},
{
"name": "Istradefylline",
"lang": "EN"
},
{
"name": "イストラデフィリン",
"lang": "JP"
}
]
] | null |
NCT00539617 | [
{
"id_field": "org_study_id",
"id_value": [
"064511"
]
},
{
"id_domain": "NCI Clinical Trial Reporting Program (CTRP)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2011-01276"
]
}
] | https://clinicaltrials.gov/study/NCT00539617 | Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery | The purpose of this study is to test the safety and effectiveness of erlotinib and FOLFOX in patients with esophageal or gastro-esophageal cancer that cannot be removed by surgery. | A Single-Arm, Phase II Study of Tarceva Plus FOLFOX6 in Patients With Unresectable or Metastatic Cancer of Esophagus or Gastroesophageal Junction | [
{
"description": "Tarceva single agent therapy: 150 mg/day PO",
"name": "Erlotinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Tarceva"
],
"type": "Drug"
},
{
"description": "5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2... | [
{
"design_group_description": "COMBINATION THERAPY PHASE: Patients receive erlotinib hydrochloride orally (PO) once daily (QD) on days 1-56. Patients also receive FOLFOX6 therapy comprising oxaliplatin intravenously (IV) over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on d... | [
"Esophageal Cancer"
] | [
"The University of California, San Francisco"
] | [
"Genentech, Inc."
] | [
[
{
"name": "盐酸厄洛替尼",
"lang": "CN"
},
{
"name": "Erlotinib Hydrochloride",
"lang": "EN"
},
{
"name": "エルロチニブ塩酸塩",
"lang": "JP"
}
],
[
{
"name": "亚叶酸钙",
"lang": "CN"
},
{
"name": "Leucovorin Calcium",
"lang": "EN"
... | null |
NCT00919295 | [
{
"id_field": "org_study_id",
"id_value": [
"323/2551(EC4)"
]
}
] | https://clinicaltrials.gov/study/NCT00919295 | Study of Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Fibromyalgia Syndrome | This study aims to investigate the anti-nociceptive biogenic amine (serotonin [5-hydroxytryptamine; 5-HT], norepinephrine [NE], dopamine [DA], and their metabolites) status, and serum levels of cytokines, BDNF and BH4 in Thai fibromyalgia syndrome (FMS) patients compared with a representative Thai population. The effic... | Study of Anti-nociceptive Biogenic Amine Status, Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Thai Fibromyalgia Syndrome Patients. | [
{
"description": "mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks",
"name": "mirtazapine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Remeron"
],
"type": "Drug"
},
{
"description": "placebo",
"name": "placebo",
"normalized_ty... | [
{
"design_group_description": "placebo",
"design_group_title": "placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_description": "placebo",
"intervention_name": "place... | [
"Fibromyalgia Syndrome"
] | [
"Mahidol University"
] | [
"Julius-Maximilians-Universität Würzburg"
] | [
[
{
"name": "米氮平",
"lang": "CN"
},
{
"name": "Mirtazapine",
"lang": "EN"
},
{
"name": "ミルタザピン",
"lang": "JP"
}
]
] | null |
NCT01822210 | [
{
"id_field": "org_study_id",
"id_value": [
"StOlav2205"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2012-002493-31"
]
}
] | https://clinicaltrials.gov/study/NCT01822210 | Botulinum Toxin for Stomach Cancer Treatment | Preclinical studies at our institution, using a genetic mouse model of gastric cancer, strongly suggest that innervation of the stomach wall is required not only for the development, but also for the progression of gastric cancer, and that denervation of the stomach either by vagotomy or by injection of botulinum toxin... | Botulinum Toxin (BOTOX) for Stomach Cancer Treatment | [
{
"description": "injection by gastroscopy (100 Allergen units)",
"name": "Botox",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Botulinum toxin"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Injection of Botox in the tumor and surrounding stomach wall.",
"design_group_title": "Botox",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": ... | [
"Stomach Neoplasms"
] | [
"St. Olavs Hospital HF"
] | [
"Norwegian University of Science & Technology"
] | [
[
{
"name": "A型肉毒毒素",
"lang": "CN"
},
{
"name": "Onabotulinumtoxin A",
"lang": "EN"
},
{
"name": "A 型ボツリヌス毒素",
"lang": "JP"
}
]
] | null |
NCT00609336 | [
{
"id_field": "org_study_id",
"id_value": [
"6511"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2010-00553"
]
},
{
"id_domain": "Fred Hutchinson Cancer Research ... | https://clinicaltrials.gov/study/NCT00609336 | Perioperative Therapy for Resectable Pancreatic Cancer | This phase II trial studies how well giving combination chemotherapy together with intensity-modulated radiation therapy (IMRT) and surgery works in treating patients with localized pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, docetaxel, capecitabine, ... | A Phase II Study Induction Chemotherapy, Neoadjuvant Chemoradiotherapy, Surgical Resection and Adjuvant Chemotherapy for Patients With Locally Advanced, Resectable Pancreatic Adenocarcinoma | [
{
"description": "Given IV",
"name": "gemcitabine hydrochloride",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Gemzar",
"dFdC",
"difluorodeoxycytidine hydrochloride",
"gemcitabine"
],
"type": "Drug"
},
{
"description": "Given IV",
... | [
{
"design_group_description": "See Detailed Description",
"design_group_title": "Treatment (chemotherapy, radiation, pancreaticoduodenectomy)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervent... | [
"Adenocarcinoma of the Pancreas",
"Stage IA Pancreatic Cancer",
"Stage IB Pancreatic Cancer",
"Stage IIA Pancreatic Cancer",
"Stage IIB Pancreatic Cancer"
] | [
"University of Washington"
] | [
"National Cancer Institute"
] | [
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
"lang": "EN"
},
{
"name": "ゲムシタビン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "多西他赛",
"lang": "CN"
},
{
"name": "Docetaxel",
"lang": "EN"
},
... | null |
NCT02735629 | [
{
"id_field": "org_study_id",
"id_value": [
"CRTX-05"
]
}
] | https://clinicaltrials.gov/study/NCT02735629 | Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia | The study is an investigation to assess the capacity of ascending doses of CX1739 to antagonize the respiratory depressive effect of remifentanil. The study will also investigate whether ascending doses of CX1739 reduce the analgesic effect of remifentanil or alter the BIS measure of sedation and will evaluate the safe... | Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia | [
{
"description": "Ampakine CX1739 - 300 mg",
"name": "CX1739 - 300 mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Low dose"
],
"type": "Drug"
},
{
"description": "CX1739 - 600 mg",
"name": "CX1739 - 600 mg",
"normalized_type": "3d1aa88261d6... | [
{
"design_group_description": "Study Drug - low dose",
"design_group_title": "CX1739 - 300 mg",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Ampakine CX1739 - 300 mg",
... | [
"Opiate Induced Respiratory Depression"
] | [
"RespireRx Pharmaceuticals, Inc."
] | [
"Duke University"
] | [
[
{
"name": "CX-1739",
"lang": "EN"
}
]
] | null |
NCT06660368 | [
{
"id_field": "org_study_id",
"id_value": [
"MCC-23154"
]
}
] | https://clinicaltrials.gov/study/NCT06660368 | BCL2i CLAG-M in R/R Acute Myeloid Leukemia | This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD) clearance and event-free survival. Investigators hypothesize that the addition of venetoclax... | A Prospective, Multicenter, Randomized, Open-Label, Phase II Study of Salvage BCL2i Plus CLAG-M in Relapsed or Refractory Acute Myeloid Leukemia | [
{
"description": "Filgrastim/G-CSF 300 mcg/day for 6 days beginning 24 hours prior to multiagent chemotherapy (days 0-5), cladribine 5 mg/m2 given intravenously over 2 hours for 5 consecutive days (days 1-5), cytarabine given IV over 4 hours for 5 consecutive days (days 1-5) beginning 2 hours after the completi... | [
{
"design_group_description": "Study participants will receive CLAG-M (cladribine, cytarabine, G-CSF, mitoxantrone) and Venetoclax",
"design_group_title": "CLAG-based therapy with venetoclax",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",... | [
"Relapsed or Refractory Acute Myeloid Leukemia (AML)"
] | [
"H. Lee Moffitt Cancer Center & Research Institute, Inc."
] | [
"AbbVie, Inc."
] | [
[
{
"name": "克拉屈滨",
"lang": "CN"
},
{
"name": "Cladribine",
"lang": "EN"
},
{
"name": "クラドリビン",
"lang": "JP"
}
],
[
{
"name": "维奈克拉",
"lang": "CN"
},
{
"name": "Venetoclax",
"lang": "EN"
},
{
"name": "ベ... | null |
NCT04138628 | [
{
"id_field": "org_study_id",
"id_value": [
"DaBlaCa-14"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2019-001679-36"
]
},
{
"id_field": "acronym",
"id_value": [
"TOMBOLA"
]
}
] | https://clinicaltrials.gov/study/NCT04138628 | Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy | Immunotherapy (checkpoint inhibitors) is approved as first and second line treatment to patients with metastatic bladder cancer. However, response rates are low and no biomarkers have yet shown strong predictive value for patient selection. Moreover, the term 'metastatic' is based on metastases visible on conventional ... | Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy | [
{
"description": "The study drug will be given according to current recommendations as systemic treatment every third week for 12 months or until progression. Treatment will be initiated within 28 days of detection of ctDNA.",
"name": "Atezolizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b"... | [
{
"design_group_description": "Flat dose 1200 mg Atezolizumab every three weeks for up to 13 months",
"design_group_title": "ctDNA screening arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interv... | [
"Bladder Cancer",
"Bladder Cancer, Metastatic"
] | [
"Århus Universitetshospital"
] | [
"Aalborg University Hospital",
"Århus Universitetshospital",
"Odense University Hospital",
"Herlev Hospital",
"Rigshospitalet"
] | [
[
{
"name": "阿替利珠单抗",
"lang": "CN"
},
{
"name": "Atezolizumab",
"lang": "EN"
},
{
"name": "アテゾリズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2e83a9e5232258a83d52a5ea85088ed9",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "TOMBOLA"
}
] |
NCT01707615 | [
{
"id_field": "org_study_id",
"id_value": [
"2010GGC10294"
]
},
{
"id_field": "acronym",
"id_value": [
"GSPE"
]
}
] | https://clinicaltrials.gov/study/NCT01707615 | Beneficial Effects of Grape Seed Proanthocyanidin Extrat on Progression of Atherosclerotic Plaques in Clinical Use | The purpose of this study is to investigate the antiatherogenic effect of GSPE in clinical use | Beneficial Effects of Grape Seed Proanthocyanidin Extrat on Progression of Carotid Intima-media Thickness and Atherosclerotic Plaques in Clinical Use | [
{
"description": "GSPE 240 mg/day (120mg bid)",
"name": "GSPE",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Grape seed proanthocyanidin extrat"
],
"type": "Drug"
},
{
"description": "dietary modification making the total ingestion of calories into st... | [
{
"design_group_description": "In the control group, all patients were enrolled in a lifestyle intervention",
"design_group_title": "control group",
"design_group_type": "Other",
"intervention": [
{
"intervention_description": "dietary modification making the total ingestion of calorie... | [
"Atherosclerosis of Arteries of the Extremities, Unspecified"
] | [
"Shandong University"
] | [
"National Natural Science Foundation of China"
] | [
[
{
"name": "葡萄籽提取物",
"lang": "CN"
},
{
"name": "Grape Seed Extract",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "GSPE"
}
] |
NCT03885245 | [
{
"id_field": "org_study_id",
"id_value": [
"19-0219"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01HL146542"
]
},
{
"id_field": "acronym",
"id_value": [
"SANDIA"
]
}
] | https://clinicaltrials.gov/study/NCT03885245 | Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes | Patients with obese late onset (after childhood) asthma can have lower FeNO levels, yet be highly symptomatic and poorly responsive to inhaled steroids. This is a common asthma phenotype, particularly among females. This reduction of NO occurs through increased arginase activity and uncoupling of NO synthase (NOS), by ... | Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes to Increase Airway L-arginine/ADMA Ratio and Improve Asthma Control | [
{
"description": "7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline",
"name": "L-ctirulline",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"L-citrulline"
],
"type": "Drug"
},
{
"description": "7 weeks... | [
{
"design_group_description": "L-citrulline with a dose of 15 g/day will be administered in powder form that is mixed with water and taken orally, continuously and daily for at least 7 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 5 weeks and then enter crossover phase of an additi... | [
"Asthma",
"Obesity"
] | [
"University of Colorado Denver"
] | [
"National Heart, Lung & Blood Institute",
"National Institutes of Health",
"Duke University"
] | [
[
{
"name": "L-Citrulline",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SANDIA"
}
] |
NCT05432414 | [
{
"id_field": "org_study_id",
"id_value": [
"POM-MM-003"
]
}
] | https://clinicaltrials.gov/study/NCT05432414 | PVd Versus Vd in NDMM Patients With RI | This is a multicenter, randomized controlled, open-label study, and the purpose of this study is to compare the efficiency and safety of PVD regimen (Pomalidomide & Bortezomib & Dexamethasone) versus VD regimen (Bortezomib & Dexamethasone) in NDMM patients with RI. The main efficacy indicator is VGPR after 4 cycles of ... | Pomalidomide, Bortezomib and Dexamethasone (PVd) Versus Bortezomib and Dexamethasone (Vd) in NDMM Patients With Renal Injury (RI)：A Multicenter, Randomized Controlled, Open-label Trial. | [
{
"description": "Pomalidomide was administered orally at a dose of 4 mg on days 1-14 of each cycle.",
"name": "pomalidomide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CC-4047"
],
"type": "Drug"
},
{
"description": "Bortezomib was administered int... | [
{
"design_group_description": "Each cycle is 21 days, after 2 cycles, patients who reached MR continued treatment for 2 cycles, 4 cycles in total. Subsequent treatment regimens after 4 cycles of induction therapy were determined by the investigator.",
"design_group_title": "Pomalidomide, Bortezomib and Dexa... | [
"Multiple Myeloma"
] | [
"Shanghai Renji Hospital"
] | [
"The First Affiliated Hospital of Ningbo University",
"Xinhua Hospital",
"Shanghai Changzheng Hospital",
"Peking University Shenzhen Hospital",
"Peking University People's Hospital",
"Third Affiliated Hospital of Nanjing Medical University",
"Chengdu No. 3 People's Hospital",
"The First Affiliated Hos... | [
[
{
"name": "地塞米松磷酸钠",
"lang": "CN"
},
{
"name": "Dexamethasone Sodium Phosphate",
"lang": "EN"
},
{
"name": "デキサメタゾンリン酸エステルナトリウム",
"lang": "JP"
}
],
[
{
"name": "泊马度胺",
"lang": "CN"
},
{
"name": "Pomalidomide",
"lan... | [
{
"identifier_source": [
{
"code": "e042a5258ea8322ddeeed825a8a22e39",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "POM-MM-003"
}
] |
NCT04539951 | [
{
"id_field": "org_study_id",
"id_value": [
"CRC2018ZD03"
]
},
{
"id_field": "acronym",
"id_value": [
"Proceed"
]
}
] | https://clinicaltrials.gov/study/NCT04539951 | Pragmatic Trial of Obsessive-compulsive Disorder | This study includes a sequenced clinical trial in order to assess the efficacy of several switching or augment strategies when initial treatment is ineffective，and to provide strong evidence for clinical practice and international guidelines for Obsessive-Compulsive Disorder treatments. | A Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD | [
{
"description": "All included participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of resp... | [
{
"design_group_description": "In experimental phase I, all recruited subjects provide written informed consent before any related procedures. Participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated... | [
"Obsessive-Compulsive Disorder"
] | [
"Shanghai Mental Health Center"
] | [
"Nanjing Medical University",
"Kunming Medical College No. 1 Attached Hospital",
"Henan Medical University",
"Guizhou Provincial People's Hospital",
"The First Affiliated Hospital of Jinan University",
"General Hospital of Ningxia Medical University",
"West China Hospital",
"The First Affiliated Hospi... | [
[
{
"name": "阿立哌唑",
"lang": "CN"
},
{
"name": "Aripiprazole",
"lang": "EN"
},
{
"name": "アリピプラゾール水和物",
"lang": "JP"
}
],
[
{
"name": "马来酸氟伏沙明",
"lang": "CN"
},
{
"name": "Fluvoxamine Maleate",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Proceed"
}
] |
NCT00080236 | [
{
"id_field": "org_study_id",
"id_value": [
"CL-000006556-PRO-0006"
]
}
] | https://clinicaltrials.gov/study/NCT00080236 | Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation | The purpose of the study is to test the safety and effectiveness of IDN-6556 in preventing liver damage that normally occurs when livers are transported before being transplanted and in the immediate post-transplant period. | Safety, Tolerability and Efficacy Study of a Caspase Inhibitor, IDN-6556, in Patients Undergoing Orthotopic Liver Transplantation (OLT) | [
{
"name": "IDN-6556",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "Donor organ placebo and Recipient placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_name": "Placebo",
"intervention_type": "Drug",
"norma... | [
"Liver Transplantation",
"Hepatitis",
"Cholestasis",
"Carcinoma, Hepatocellular"
] | [
"Conatus Pharmaceuticals, Inc."
] | [
"Idun Pharmaceuticals, Inc."
] | [
[
{
"name": "恩利卡生",
"lang": "CN"
},
{
"name": "Emricasan",
"lang": "EN"
}
]
] | null |
NCT01348412 | [
{
"id_field": "org_study_id",
"id_value": [
"0329-1ghfr09"
]
},
{
"id_field": "acronym",
"id_value": [
"HEARTO"
]
}
] | https://clinicaltrials.gov/study/NCT01348412 | Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure | Standard treatment of metastatic colorectal cancers relies on fluoropyrimidines, irinotecan alone or in association with fluoropyrimidines, oxaliplatin in association with fluoropyrimidines, bevacizumab and anti EGFR antibodies. After failure of classical regimen the national reference frame on the basis of phase II st... | Phase II Randomized Study Comparing the Association of Intraarterial Perfusion of Raltitrexed and Oxaliplatin Versus Standard Chemotherapy Using Intravenous Perfusion for Colorectal Cancer Patient With Metastases Localized to Liver After Failure of Conventional Treatments. | [
{
"description": "130 mg/m²Every 21 days",
"name": "oxaliplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "3 mg/m² with a maximum of 6 mg every 21 days",
"name": "raltitrexed",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "Hepatic artery infusion through an implanted arterial catheter of the combination of raltitrexed (3 mg/m ²) and oxaliplatin (100 mg/m ²) every 21 days.",
"design_group_title": "ARM A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562... | [
"Colorectal Cancer",
"Liver Metastases"
] | [
"Centre Georges François Leclerc"
] | [
"National Cancer Institute",
"Hospira, Inc."
] | [
[
{
"name": "奥沙利铂",
"lang": "CN"
},
{
"name": "Oxaliplatin",
"lang": "EN"
},
{
"name": "オキサリプラチン",
"lang": "JP"
}
],
[
{
"name": "雷替曲塞",
"lang": "CN"
},
{
"name": "Raltitrexed",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "HEARTO"
}
] |
NCT01328535 | [
{
"id_field": "org_study_id",
"id_value": [
"MC1076"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2011-00449"
]
},
{
"id_domain": "Mayo Clinic Cancer Center ID",... | https://clinicaltrials.gov/study/NCT01328535 | Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | This clinical trial studies individualized temozolomide (TMZ) in treating patients with stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as TMZ, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving TMZ at dif... | Individualized (Timed) Temozolomide Administration as a Means of Immune Reconstitution in Patients With Metastatic Melanoma | [
{
"description": "Given PO",
"name": "temozolomide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"SCH 52365",
"TMZ",
"Temodal",
"Temodar"
],
"type": "Drug"
},
{
"description": "Correlative studies",
"name": "flow cytometry",
... | [
{
"design_group_description": "Patients with an established biorhythm receive TMZ PO on recommended day for 5 days. Treatment repeats every 21-42 days until disease progression or unacceptable toxicity. Patients without an established biorhythm receive TMZ PO on days 1-5. Courses repeat every 28 days until dise... | [
"Recurrent Melanoma",
"Stage IV Melanoma"
] | [
"Mayo Clinic"
] | [
"National Cancer Institute"
] | [
[
{
"name": "替莫唑胺",
"lang": "CN"
},
{
"name": "Temozolomide",
"lang": "EN"
},
{
"name": "テモゾロミド",
"lang": "JP"
}
]
] | null |
NCT06087614 | [
{
"id_field": "org_study_id",
"id_value": [
"Res/SCM/58/2023/33"
]
},
{
"id_field": "acronym",
"id_value": [
"DE-HyART"
]
}
] | https://clinicaltrials.gov/study/NCT06087614 | Dose Escalation Using Hypoxia-adjusted Radiotherapy | DE-HyART is a phase II clinical trial aimed at understanding the effects of escalating radiation doses to hypoxic sub-volumes inherent to squamous cell head and neck cancer. The study is aimed at assessing locoregional control, feasibility, and acceptable toxicity with such a strategy. | A Phase II Randomised Controlled Study Assessing the Role of Dose Escalation Using [18F] FMISO PET CT in Head and Neck Cancer: The DE-HyART (Dose Escalation Using Hypoxia-adjusted Radiotherapy) Protocol | [
{
"description": "The HSV delineation will be done for patients in arm 3 using baseline FMISO. The HSV will be contoured and adjusted according to the second FMISO scan done between the 4th - the 5th week of radiation treatment. A planning CT will also be repeated at the time for adjusting the HSV to account fo... | [
{
"design_group_description": "The radiation dose will be similar to 'arm 2'. In addition, the HSV identified on baseline FMISO scans will be contoured, and an isotropic margin of 5 mm will be given. This volume will be boosted in phase II to a total dose of 80 Gy. (Addition of 30 Gy in 3 Gy daily fraction adde... | [
"Head and Neck Squamous Cell Carcinoma"
] | [
"Rajiv Gandhi Cancer Institute & Research Center"
] | [
"Varian Ltd."
] | [
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
"name": "シスプラチン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "5a202240e9da58a303a222de59ee255a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "CTRI/2024/04/065373"
},
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
... |
NCT02276937 | [
{
"id_field": "org_study_id",
"id_value": [
"CTR-001"
]
},
{
"id_domain": "UMIN CTR",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"UMIN000014926"
]
}
] | https://clinicaltrials.gov/study/NCT02276937 | Randomized Phase IIb Trial of DVC1-0101 | DVC1-0101 is a gene therapy medicine to treat peripheral arterial disease (PAD) based on recombinant F-gene-deleted, non-transmissible Sendai virus (rSeV/dF) expressing human fibroblast growth factor-2 (FGF-2) gene.<br/>The primary objective of the current Phase IIb study is to investigate the clinical efficacy of DVC1... | DVC1-0101 for Intermittent Claudication Secondary to Peripheral Artery Disease: a Randomized Phase IIb Trial | [
{
"description": "The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.",
"name":... | [
{
"design_group_description": "Placebo control",
"design_group_title": "Placebo (0 ciu/limb)",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_description": "The investigational prod... | [
"Intermittent Claudication",
"Peripheral Arterial Disease"
] | [
"Kyushu University"
] | [
"Japan Agency for Medical Research & Development"
] | [
[
{
"name": "成纤维细胞生长因子2基因疗法(Id Pharma Co., Ltd.)",
"lang": "CN"
},
{
"name": "Fibroblast growth factor 2 gene therapy(Id Pharma Co., Ltd.)",
"lang": "EN"
}
]
] | null |
NCT04017845 | [
{
"id_field": "org_study_id",
"id_value": [
"3Al-KindyCM"
]
}
] | https://clinicaltrials.gov/study/NCT04017845 | Screening for Colorectal Cancer in Average and High Risk Population | The existing evidence from epidemiological studies and randomized controlled trials has consistently assures the cost effectiveness and the influential role of screening in reducing incidence rates and deaths caused by Colorectal Cancer (CRC). Population based organized screening programmes, which should be considered ... | Screening for Colorectal Cancer in Average and High Risk Iraqi Population: A Pilot Study | [
{
"description": "Screenees were supplied with two fecal collection devices and asked to collect two specimens from two consecutive Different Bowel Movement Samples (DBMS) or, in case of infrequent bowel movements, from the Same Bowel Movement Sample (SBMS).Instruction stressed that after collection the device ... | [
{
"design_group_description": "Precolonoscopy cleansing regimen and referral to conventional colonoscopy is based on Positive FIT (level ≥75ng/ml) in any of the two collected samples. Histopathological examinations of screen-detected lesions are reported and lesion with the worst prognosis is indicated as the f... | [
"Colorectal Neoplasms",
"Colorectal Cancer",
"Adenomatous Polyp of Colon"
] | [
"Al-Kindy College of Medicine"
] | [
"Al-Kindy College of Medicine"
] | [
[
{
"name": "利多卡因/三苄糖苷",
"lang": "CN"
},
{
"name": "Lidocaine/Tribenoside",
"lang": "EN"
},
{
"name": "トリベノシド/リドカイン",
"lang": "JP"
}
],
[
{
"name": "盐酸地尔硫卓",
"lang": "CN"
},
{
"name": "Ditiazem Hydrochloride",
"lang"... | null |
NCT05495464 | [
{
"id_field": "org_study_id",
"id_value": [
"2020-0872"
]
},
{
"id_domain": "NCI-CTRP Clinical Trials Reporting Registry",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"NCI-2022-06281"
]
},
{
"id_field": "secondary_id",
"id_valu... | https://clinicaltrials.gov/study/NCT05495464 | A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | To learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease. | A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | [
{
"description": "Given by PO",
"name": "Acalabrutinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Given by IV (vein)",
"name": "Rituximab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Rituxan"
... | [
{
"design_group_description": "Participants may receive acalabrutinib and rituximab for up to 12 cycles. Each cycle is 28 days.",
"design_group_title": "Acalabrutinib and Rituximab (Part 1)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
... | [
"Lymphoma",
"Mantle Cell Lymphoma"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"Kite Pharma, Inc.",
"Acerta Pharma BV"
] | [
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang": "JP"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
... | [
{
"identifier_source": [
{
"code": "934843ed588808d285582aeea20eaa29",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "WINDOW-3"
}
] |
NCT04657861 | [
{
"id_field": "org_study_id",
"id_value": [
"APRIL-001"
]
}
] | https://clinicaltrials.gov/study/NCT04657861 | APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma | A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma | Clinical Trial for the Safety and Efficacy of APRIL CAR-T Cells Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma | [
{
"description": "Each subject receive APRIL CAR T-cells by intravenous infusion",
"name": "APRIL CAR-T cells",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"APRIL CAR-T cells injection"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Each subject receive APRIL CAR T-cells by intravenous infusion",
"design_group_title": "Administration of APRIL CAR T-cells",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Multiple Myeloma in Relapse",
"Multiple Myeloma, Refractory"
] | [
"Zhejiang University"
] | [
"Shanghai Yake Biotechnology Co., Ltd"
] | [
[
{
"name": "APRIL chimeric antigen receptor-T cell therapy (Yake Biotechnology)",
"lang": "EN"
}
]
] | null |
NCT02577575 | [
{
"id_field": "org_study_id",
"id_value": [
"10-01508"
]
},
{
"id_field": "acronym",
"id_value": [
"OT"
]
}
] | https://clinicaltrials.gov/study/NCT02577575 | Adult Oxytocin Study | In this study, investigators will examine the behavioral effects and neurophysiological mechanisms of the pro-social neuropeptide oxytocin in patients with recent-onset schizophrenia. Such research is a necessary first step towards identifying whether intranasal oxytocin administration can serve as an adjunct treatment... | The Effects of Oxytocin on Social Cognition in Patients With Schizophrenia | [
{
"description": "40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.",
"name": "Oxytocin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Syntocinon"
],
"type": "Drug"
},
{
"description": "40 IU of... | [
{
"design_group_description": "40 IU Oxytocin",
"design_group_title": "Oxytocin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "40 IU of the oxytocin will be administered ... | [
"Schizophrenia",
"Oxytocin",
"Social Cognition"
] | [
"The University of California, San Francisco"
] | [
"San Francisco VA Medical Center"
] | [
[
{
"name": "缩宫素",
"lang": "CN"
},
{
"name": "Oxytocin",
"lang": "EN"
},
{
"name": "オキシトシン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "OT"
}
] |
NCT02828033 | [
{
"id_field": "org_study_id",
"id_value": [
"Rilonacept IIS 1604"
]
}
] | https://clinicaltrials.gov/study/NCT02828033 | Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss | This study is an open label proof of concept study of rilonacept for patients with ANSHL | A Pilot Trial of Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss | [
{
"description": "All patients will receive rilonacept with an initial loading dose of 320 mg delivered as two, 2-mL, subcutaneous injections of 160 mg each given on the same day at two different sites. The initial dose will be administered at the study site by study personnel. Dosing will then be a once-weekly... | [
{
"design_group_description": "A loading dose of 320 mg the first dose then be a once-weekly injection of 160 mg for 24 weeks",
"design_group_title": "Rilonacept",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Autoimmune Neurosensory Hearing Loss (ANSHL)"
] | [
"Metroplex Clinical Research Center"
] | [
"Regeneron Pharmaceuticals, Inc."
] | [
[
{
"name": "利纳西普",
"lang": "CN"
},
{
"name": "Rilonacept",
"lang": "EN"
}
]
] | null |
NCT00585156 | [
{
"id_field": "org_study_id",
"id_value": [
"IIR#2005-0300"
]
},
{
"id_field": "secondary_id",
"id_value": [
"IIR#2005-0300"
]
}
] | https://clinicaltrials.gov/study/NCT00585156 | The Effects of Celecoxib on Bone Ingrowth | The purpose of this study is to evaluate the effect of Celebrex on bone growth into porous coated implants, following postoperative total knee arthroplasty administration of Celebrex for pain relief. | The Effects of Celecoxib on Bone Ingrowth in Porous Coated Titanium Ceramic Implants in Humans | [
{
"description": "Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week pe... | [
{
"design_group_description": "Celebrex treatment group",
"design_group_title": "Arm #1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Twelve hours prior to their first t... | [
"Bone Ingrowth",
"Pain"
] | [
"University of Utah"
] | [
"Pfizer Inc."
] | [
[
{
"name": "塞来昔布",
"lang": "CN"
},
{
"name": "Celecoxib",
"lang": "EN"
},
{
"name": "セレコキシブ",
"lang": "JP"
}
]
] | null |
NCT03979898 | [
{
"id_field": "org_study_id",
"id_value": [
"biostar-CP"
]
},
{
"id_field": "acronym",
"id_value": [
"CP"
]
}
] | https://clinicaltrials.gov/study/NCT03979898 | Safety and Effectiveness of Autologous Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With CP | Safety and Effectiveness of Autologous Adipose Tissue Derived mesenchymal Stem Cell Implantation in Patients with CP | Safety and Effectiveness of Autologous Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With Cerebral Palsy (CP) | [
{
"description": "Intravenous injection of Autologous Adipose derived mesenchymal stem cells. Dose : 15kg below : 0.5x10^7cells/5mL 15kg <br/> 25kg : 1x10^8cells/10mL 25kg over : 1.5x10^8cells/15mL",
"name": "ASTROSTEM",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"A... | [
{
"design_group_description": "Autologous Adipose Tissue Derived Mesenchymal Stem Cells",
"design_group_title": "Astrostem",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "... | [
"Cerebral Palsy"
] | [
"R Bio Co., Ltd."
] | [
"Kyung Hee University Hospital at Gangdong"
] | [
[
{
"name": "Autologous Adipose Derived Mesenchymal Stem Cells(American CryoStem Co)",
"lang": "EN"
}
],
[
{
"name": "Autologous adipose tissue-derived mesenchymal stem cells (R Bio)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CP"
}
] |
NCT06065189 | [
{
"id_field": "org_study_id",
"id_value": [
"CS-101-03"
]
}
] | https://clinicaltrials.gov/study/NCT06065189 | Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major | The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of base-edited autologous hematopoietic stem cell transplantation(CS-101) in treating patients with β-thalassemia major. | Evaluation and Promotion of Key Technologies of Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major | [
{
"description": "Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique",
"name": "CS-101 injection",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Autologous CD34+(cluster of differentiation 34) hematopoietic stem cell suspension modified by in vitro base editing technique",
"design_group_title": "CS-101 injection",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22c... | [
"Beta-Thalassemia"
] | [
"Paediatrics Hospital Affiliated To Fudan University"
] | [
"CorrectSequence Therapeutics Co., Ltd."
] | [
[
{
"name": "CS-101",
"lang": "EN"
}
]
] | null |
NCT00965666 | [
{
"id_field": "org_study_id",
"id_value": [
"05-07-24"
]
}
] | https://clinicaltrials.gov/study/NCT00965666 | Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia | The purpose of this research study is to evaluate the safety of the drug Etanercept (Enbrel) and to determine if this drug can help in the treatment of early bone marrow failure in patients with Fanconi anemia. | Etanercept (Enbrel) in Children With Fanconi Anemia and Early Bone Marrow Failure: A Pilot Study | [
{
"description": "All qualified subjects receive 24 weekly subcutaneous injections of Etanercept.",
"name": "Etanercept",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Enbrel"
],
"type": "Drug"
}
] | [
{
"design_group_title": "Open Label",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "All qualified subjects receive 24 weekly subcutaneous injections of Etanercept.",
"... | [
"Fanconi Anemia"
] | [
"Children's Hospital & Medical Center"
] | [
"Amgen, Inc."
] | [
[
{
"name": "依那西普",
"lang": "CN"
},
{
"name": "Etanercept",
"lang": "EN"
},
{
"name": "エタネルセプト（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT01852071 | [
{
"id_field": "org_study_id",
"id_value": [
"EFS-ADA"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"U01AI100801"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"2P01HL0... | https://clinicaltrials.gov/study/NCT01852071 | Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene | The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from the bone marrow (BM) of ADA-deficient SCID infants and children following human ADA cDNA transfer by the EFS-ADA lentiviral vector. The level of gene transfer in blood cells and immune... | Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA Complementary DNA (cDNA) by the EFS-ADA Lentiviral Vector for Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID) | [
{
"description": "autologous EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously",
"name": "Infusion of autologous EFS-ADA LV CD34+ (OTL-101)",
"normalized_type": "288887f0545745558ff1ab1c85757552",
"other_name": [
"OTL-101"
],
"type": "Genetic"
},
{
"description": "Busu... | [
{
"design_group_description": "Infusion of autologous EFS-ADA Lentiviral (LV) CD34+ cells",
"design_group_title": "Gene Therapy",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descriptio... | [
"ADA-SCID"
] | [
"University of California, Los Angeles"
] | [
"National Heart, Lung & Blood Institute",
"National Human Genome Research Institute",
"National Institute of Allergy & Infectious Diseases",
"Orchard Therapeutics Plc"
] | [
[
{
"name": "白消安",
"lang": "CN"
},
{
"name": "Busulfan",
"lang": "EN"
},
{
"name": "ブスルファン",
"lang": "JP"
}
],
[
{
"name": "OTL-101",
"lang": "EN"
}
],
[
{
"name": "Pegademase",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "948ea985a24ad02435e9e500e08adea3",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "EFS-ADA"
}
] |
NCT02425748 | [
{
"id_field": "org_study_id",
"id_value": [
"Gd T cell and lung cancer"
]
}
] | https://clinicaltrials.gov/study/NCT02425748 | Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation) | In this study, effects of γδT cells on human non small lung cancer ( without EGFR mutation) in combination with tumor reducing surgery, for example cryosurgery going to be investigated. | γδ T Cell Immunotherapy for Treatment of | [
{
"description": "DC-CIK cells will be used against tumor cells.",
"name": "DC-CIK",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"single_or_multi": "single_drug",
"type": "Biological"
},
{
"description": "γδ T cells will be used against non small lung tumor.",
"name": "γδ ... | [
{
"design_group_description": "DC-CIK cells will be used against tumor cells.",
"design_group_title": "Group A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "DC-CIK cells... | [
"Lung Cancer"
] | [
null
] | [
"Jinan University"
] | [
[
{
"name": "DC-CIK(Fuda Cancer Hospital)",
"lang": "EN"
}
],
[
{
"name": "γδ T Cell(Fuda Cancer Hospital)",
"lang": "EN"
}
]
] | null |
NCT03672188 | [
{
"id_field": "org_study_id",
"id_value": [
"VIR-2218-1001"
]
}
] | https://clinicaltrials.gov/study/NCT03672188 | Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B | This is a phase 1/2 study in which healthy adult subjects and subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 or placebo and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity (only in subjects with chronic HBV).<br/>In the single ascending dose (SAD) part,... | A Phase 1/2, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 | [
{
"description": "VIR-2218 given by subcutaneous injection",
"name": "VIR-2218",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Sterile normal saline (0.9% NaCl) given by subcutaneous injection",
"name": "Placebo",
"normalized_type": "3d1aa... | [
{
"design_group_description": "Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC",
"design_group_title": "Part A: SAD VIR-2218 50 mg",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Chronic Hepatitis B"
] | [
"Vir Biotechnology, Inc."
] | [
"Alnylam Pharmaceuticals, Inc."
] | [
[
{
"name": "艾博西兰",
"lang": "CN"
},
{
"name": "Elebsiran",
"lang": "EN"
}
]
] | null |
NCT04486352 | [
{
"id_field": "org_study_id",
"id_value": [
"AFT-50"
]
},
{
"id_field": "acronym",
"id_value": [
"EndoMAP"
]
}
] | https://clinicaltrials.gov/study/NCT04486352 | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous bas... | A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer | [
{
"description": "Atezolizumab will be given to participants intravenously at a dosage of 1680 mg on day 1 of each 28-day cycle.",
"name": "Atezolizumab - 28 Day Cycle",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"L01XC32",
"Tecentriq"
],
"type": "Drug... | [
{
"design_group_description": "Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with no specified gene signatures will be enrolled in this cohort. Twenty participants will be enrolled. Once twenty participants are enrolled, the cohort will be closed... | [
"Endometrial Cancer"
] | [
"Alliance Foundation Trials LLC"
] | [
"Genentech, Inc.",
"Pfizer Inc.",
"Foundation Medicine, Inc.",
"Eli Lilly & Co."
] | [
[
{
"name": "吉雷司群",
"lang": "CN"
},
{
"name": "Giredestrant",
"lang": "EN"
}
],
[
{
"name": "恩美曲妥珠单抗",
"lang": "CN"
},
{
"name": "ADO-Trastuzumab Emtansine",
"lang": "EN"
},
{
"name": "トラスツズマブ エムタンシン（遺伝子組換え）",
"lang"... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EndoMAP"
}
] |
NCT04471727 | [
{
"id_field": "org_study_id",
"id_value": [
"HPN328-4001"
]
},
{
"id_domain": "MSD",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"MK-6070-001"
]
},
{
"id_domain": "Harpoon Therapeutics Inc. ID",
"id_field": "secondary_id",
... | https://clinicaltrials.gov/study/NCT04471727 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of Delta-like Canonical Notch Ligand 3 (DLL3)... | A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab or Ifinatamab Deruxtecan (I-DXd) in Patients With Advanced Cancers Associated With Expression of Delta-like Canonical Notch Ligand 3 (DLL3). | [
{
"description": "IV infusion",
"name": "Gocatamig",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"HPN328",
"MK-6070"
],
"type": "Biological"
},
{
"description": "IV infusion",
"name": "Atezolizumab",
"normalized_type": "30faef638ae74cc79... | [
{
"design_group_description": "Participants will receive gocatamig once weekly (Q1W) via intravenous (IV) infusion during each 21-day cycle. Dose escalation may continue until one or more RDEs are identified, participant discontinuation or the Sponsor decides to stop enrollment.",
"design_group_title": "Goc... | [
"Small-Cell Lung Cancer",
"Neuroendocrine Carcinoma"
] | [
"Harpoon Therapeutics, Inc."
] | [
"Daiichi Sankyo Co., Ltd."
] | [
[
{
"name": "Gocatamig",
"lang": "EN"
}
],
[
{
"name": "Ifinatamab deruxtecan",
"lang": "EN"
},
{
"name": "イフィナタマブ デルクステカン（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "阿替利珠单抗",
"lang": "CN"
},
{
"name": "Atezolizumab",
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "83d550558e39aa3a44255a8525828e23",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "MK-6070-001"
},
{
"identifier_source": [
... |
NCT01989897 | [
{
"id_field": "org_study_id",
"id_value": [
"2012H0217"
]
}
] | https://clinicaltrials.gov/study/NCT01989897 | Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests | This is a double-blind study with respect to the diluents used, with patients known to be allergic to the specific allergen tested. Three study sites will be involved, each testing one allergen (Cat, Mite, Timothy grass pollen). Subjects who are known to be allergic to the allergen in question will be tested with seria... | Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests | [
{
"name": "saline with 1mg/ml Histamine base",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "diluent, saline with HSA--phenol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"HSA 300mcg/ml (0.03%) and Saline"
],
... | [
{
"design_group_description": "Negative control = diluent, saline with HSA--phenol Positive control = saline with 1mg/ml Histamine base",
"design_group_title": "diluents",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": ... | [
"Allergic Rhinitis"
] | [
"The Ohio State University"
] | [
"American College of Allergy Asthma & Immunology"
] | [
[
{
"name": "盐酸组胺",
"lang": "CN"
},
{
"name": "Histamine Dihydrochloride",
"lang": "EN"
}
]
] | null |
NCT05514990 | [
{
"id_field": "org_study_id",
"id_value": [
"16M-22-1"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2022-06505"
]
},
{
"id_domain": "USC / Norris Comprehensive C... | https://clinicaltrials.gov/study/NCT05514990 | Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial | This phase I/II trial studies the safety of the combination of bortezomib, dexamethasone, and pembrolizumab with or without pelareorep in treating patients with multiple myeloma that has come back (relapsed) or does not response to treatment (refractory). Chemotherapy drugs, such as bortezomib and dexamethasone, work i... | A Phase 1b/2 Study of Standard Doses of Bortezomib and Pembrolizumab ± Reovirus (Pelareorep) Combination Therapy in Patients With Relapsed Multiple Myeloma (AMBUSH Study) | [
{
"description": "Given SC or IV",
"name": "Bortezomib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"LDP 341",
"MLN341",
"PS-341",
"PS341",
"Velcade",
"[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]buty... | [
{
"design_group_description": "Patients receive bortezomib SC) or IV and dexamethasone PO, IV, or IM on days 1, 8, and 15 of each cycle. Patients also receive pembrolizumab IV over 30 minutes on day 9 of each cycle. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or una... | [
"Recurrent Plasma Cell Myeloma",
"Refractory Plasma Cell Myeloma"
] | [
"University of Southern California"
] | [
"National Cancer Institute"
] | [
[
{
"name": "Pelareorep",
"lang": "EN"
}
],
[
{
"name": "地塞米松磷酸钠",
"lang": "CN"
},
{
"name": "Dexamethasone Sodium Phosphate",
"lang": "EN"
},
{
"name": "デキサメタゾンリン酸エステルナトリウム",
"lang": "JP"
}
],
[
{
"name": "帕博利珠单抗",
... | null |
NCT04863885 | [
{
"id_field": "org_study_id",
"id_value": [
"MCC-20943"
]
},
{
"id_domain": "Bristol-Myers Squibb",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"CA209-63Y"
]
}
] | https://clinicaltrials.gov/study/NCT04863885 | Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients | The purpose of this study is to see how well the study drugs called Ipilimumab plus Nivolumab (IPI-NIVO) work when added to another study drug called Sacituzumab Govitecan for people who have metastatic bladder cancer. | Phase I/II Study of Ipilimumab Plus Nivolumab (IPI-NIVO) Combined With Sacituzumab Govitecan (SG)as First-line Treatment for Cisplatin-ineligible Metastatic Urothelial Carcinoma | [
{
"description": "Participants will receive Ipilimumab 3 mg/kg",
"name": "Ipilimumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Yervoy"
],
"type": "Drug"
},
{
"description": "Participants will receive Nivoumab 1mg/kg",
"name": "Nivolumab",
... | [
{
"design_group_description": "Participants will be treated at dose level 1: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 8 mg/kg IV will be administered days 1 and 8 every 3 weeks.",
"design_group_title": "Phase ... | [
"Metastatic Urothelial Carcinoma"
] | [
"H. Lee Moffitt Cancer Center & Research Institute, Inc."
] | [
"Bristol Myers Squibb Co.",
"Gilead Sciences, Inc."
] | [
[
{
"name": "伊匹木单抗",
"lang": "CN"
},
{
"name": "Ipilimumab",
"lang": "EN"
},
{
"name": "イピリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
... | [
{
"identifier_source": [
{
"code": "9022aaed29845d5552d2a8d39ae2e2e5",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan"
}
] |
NCT03607903 | [
{
"id_field": "org_study_id",
"id_value": [
"CHDR1807"
]
}
] | https://clinicaltrials.gov/study/NCT03607903 | Adalimumab Microneedles in Healthy Volunteers | Adalimumab (Humira, AbbVie) is a highly effective treatment for a variety of auto-immune/auto-inflammatory diseases including juvenile idiopathic arthritis (JIA). Adalimumab works by binding to tumor necrosis factor alpha (TNF), hereby preventing its interaction with the TNF receptor. In the presence of complement, ada... | A Randomized, Double Blind, Placebo-controlled, Double-dummy Study to Assess Microneedle Delivery in Comparison to Subcutaneous Injection of Adalimumab in Healthy Volunteers | [
{
"description": "Adalimumab intradermal using MicronJet600 microneedle from NanoPass",
"name": "Adalimumab ID",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Adalimumab subcutaneous using regular needle",
"name": "Adalimumab SC",
"n... | [
{
"design_group_description": "adalimumab SC (40 mg in 0.4 mL) and saline ID (0.9%, 0.4 mL)",
"design_group_title": "Subcutaneous adalimumab and placebo",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
... | [
"Pain",
"Injection Site"
] | [
"Centre for Human Drug Research"
] | [
"Leiden Amsterdam Center for Drug Research",
"Leids Universitair Medisch Centrum"
] | [
[
{
"name": "阿达木单抗",
"lang": "CN"
},
{
"name": "Adalimumab",
"lang": "EN"
},
{
"name": "アダリムマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT07128381 | [
{
"id_field": "org_study_id",
"id_value": [
"2025-0621"
]
},
{
"id_domain": "NCI-CTRP Clinical Trials Registry",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"NCI-2025-05876"
]
},
{
"id_field": "secondary_id",
"id_value": [
... | https://clinicaltrials.gov/study/NCT07128381 | Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) | * To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML.<br/>* To learn if axatilimab given in combination with ruxolitinib can help to control MF and CMML. | Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) | [
{
"description": "Taken orally",
"name": "Axatilimab (SNDX-6352)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Taken orally",
"name": "Ruxolitinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Participants will self-administered approximately 12 hours apart without regard to food",
"design_group_title": "Monotherapy or Combination: Treatment with Axatilimab +/- Ruxolitinib IV Q4W",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b... | [
"Myelofibrosis (MF)",
"Chronic Myelomonocytic Leukemia (CMML)"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"Incyte Corp."
] | [
[
{
"name": "艾克利单抗",
"lang": "CN"
},
{
"name": "Axatilimab-csfr",
"lang": "EN"
},
{
"name": "アキサチリマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "磷酸芦可替尼",
"lang": "CN"
},
{
"name": "Ruxolitinib Phosphate",
"lang": "EN"
... | null |
NCT00405821 | [
{
"id_field": "org_study_id",
"id_value": [
"999907032"
]
},
{
"id_domain": "NIAID Intramural IRB",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"07-I-N032"
]
}
] | https://clinicaltrials.gov/study/NCT00405821 | Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda | This study will determine whether acyclovir, a medicine used to treat herpes simplex virus 2 (HSV-2), can slow down the progression (worsening) of HIV disease in people with both HIV and HSV-2 infections. HSV-2 increases the amount of HIV virus in the blood of infected people and may make HIV progress faster. The study... | A Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir Prophylaxis Versus Placebo Among HIV-1/HSV-2 Co-Infected Individuals in Uganda | [
{
"description": "400mg twice daily for 24 months",
"name": "Acyclovir",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo tablet twice daily for 24 months",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_title": "Acyclovir 400mg tablet twice daily",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "400mg twice daily for 24 months",
"intervention_name":... | [
"HIV Infections",
"Herpes Genitalis"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
"The Johns Hopkins University",
"Translational Genomics Research Institute",
"University of Washington"
] | [
[
{
"name": "阿昔洛韦",
"lang": "CN"
},
{
"name": "Acyclovir",
"lang": "EN"
},
{
"name": "アシクロビル",
"lang": "JP"
}
]
] | null |
NCT00041028 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro00011318"
]
},
{
"id_field": "secondary_id",
"id_value": [
"DUMC-0041-M1RB00622"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NCI-2310"
]
},
{
"id_domain": "NCI",
"id_field": "secondary_id"... | https://clinicaltrials.gov/study/NCT00041028 | EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer | RATIONALE: Knowing the level of oxygen in tumor tissue may help predict the effectiveness of anticancer therapy. EF5 is a drug used in the measurement of oxygen in tumor tissue.<br/>PURPOSE: Phase II trial to study the effectiveness of EF5 in assessing tumor response to anticancer therapy in patients who have stage I, ... | Pilot Phase II Research Study of EF5 to Measure Tumor Hypoxia in Patients With Non-Small Cell Lung Cancer | [
{
"name": "EF5",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "flow cytometry",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"type": "Other"
},
{
"name": "immunohistochemistry staining method",
... | null | [
"Lung Cancer"
] | [
"Duke University"
] | [
"National Cancer Institute"
] | [
[
{
"name": "NSC-684681",
"lang": "EN"
}
]
] | null |
NCT04850898 | [
{
"id_field": "org_study_id",
"id_value": [
"SAB-176-201"
]
}
] | https://clinicaltrials.gov/study/NCT04850898 | Study of SAB-176 in Healthy Adult Participants | Healthy adult participants will be challenged with the H1N1 Influenza virus and then treated with either SAB-176 or placebo. | A Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Treatment Efficacy of SAB-176 (a Quadrivalent Anti-seasonal Influenza Immunoglobulin Product) in an H1N1 Challenge Model in Healthy Adult Participants | [
{
"description": "Treatment of influenza",
"name": "SAB-176",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Placebo Control",
"name": "Placebo",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"type": "Other"
}
] | [
{
"design_group_description": "Placebo control dosed 1 time via intravenous infusion",
"design_group_title": "Normal Saline Placebo Control",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"inter... | [
"Influenza A H1N1"
] | [
"SAB Biotherapeutics, Inc."
] | [
"hVIVO Holdings Ltd."
] | [
[
{
"name": "SAB-176",
"lang": "EN"
}
]
] | null |
NCT00015951 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000068576"
]
},
{
"id_field": "secondary_id",
"id_value": [
"MSGCC-0076"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NCI-2490"
]
}
] | https://clinicaltrials.gov/study/NCT00015951 | Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers | RATIONALE: Monoclonal antibodies such as bevacizumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may be an effective treatment for hematologic cancer.<br/>PURPOSE: Phase II trial to study ... | A Phase II Study of the Recombinant Human Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (rhuMAB VEGF) Bevacizumab (NSC #704865, IND # 7,921) Administered in Times Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Refractory and Relapsed Acute Myelogenous Leukemias (... | [
{
"name": "bevacizumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"single_or_multi": "single_drug",
"type": "Biological"
},
{
"name": "cytarabine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"... | null | [
"Leukemia",
"Myelodysplastic Syndromes"
] | [
"University of Maryland Baltimore"
] | [
"National Cancer Institute",
"University of Maryland Greenebaum Cancer Center"
] | [
[
{
"name": "盐酸米托蒽醌",
"lang": "CN"
},
{
"name": "Mitoxantrone Hydrochloride",
"lang": "EN"
},
{
"name": "ミトキサントロン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "贝伐珠单抗",
"lang": "CN"
},
{
"name": "Bevacizumab",
"lang": "EN"
... | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.